Here you are: IMGT Web resources > IMGT Repertoire (IG and TR) > Genes and clinical entities

Monoclonal antibodies with clinical indications

Definitions

monoclonal antibodies and immunoadhesins approved for therapeutic use are on the market (in 2010)

- 5 Human adalimumab
(2002)
HUMIRA® /
TRUDEXA® 		panitumumab
(2006)
VECTIBIX™ 		golimumab
(2009)
SIMPONI™ 		canakinumab
(2009)
ILARIS® 		ustekinumab
(2009)
STELARA™
- 5 Murine muromonab-CD3
(1992)
ORTHOCLONE OKT3® 		edrecolomab
(1995)
PANOREX® 		capromab
(1996)
PROSTASCINT® 		ibritumomab tiuxetan
(2002)
ZEVALIN® 		tositumomab
(2003)
BEXXAR®
- 5 Chimeric abciximab
(1994)
REOPRO® 		rituximab
(1997)
MABTHERA® /
RITUXAN® 		basiliximab
(1998)
SIMULECT® 		infliximab
(1998)
REMICADE® 		cetuximab
(2004)
ERBITUX®
- 11 Humanized daclizumab
(1997)
ZENAPAX® 		palivizumab
(1998)
SYNAGIS® 		trastuzumab
(1998)
HERCEPTIN® 		alemtuzumab
(2001)
CAMPATH® /
MABCAMPATH® 		omalizumab
(2003)
XOLAIR® 		ranibizumab
(2006)
LUCENTIS® 		eculizumab
(2007)
SOLIRIS™ 		natalizumab
(2008)
TYSABRI® /
ANTEGREN® (formerly) 		bevacizumab
(2008)
AVASTIN® 		certolizumab pegol
(2008)
CIMZIA® 		nimotuzumab
(2008)
THERACIM®
- 4 Immunoadhesin etanercept
(1998)
ENBREL® 		alefacept
(2003)
AMEVIVE® 		abatacept
(2005)
ORENCIA® 		rilonacept
(2008)
ARCALYST™

The INN is followed by the date of first FDA approval and the commercial mark(s).

Development status

These phases are defined by the FDA in the Code of Federal Regulations.

print To print these tables please use Internet Explorer and print in Landscape format and A3 paper size.

Human

Number of results: 72

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT/mAb-DB receptor type IMGT/mAb-DB species Isotype and format Fusion protein format Conjugated/ Radiolabelled Specificity target name
[species]		 Origin clone species Origin clone name Company Clinical indication Development status Regulatory agency status and year Expression Application Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
165 adalimumab 7860 82
(1999)		 44
(2000)		 D2E7 HUMIRA® (EU/US)
TRUDEXA® (EU) 		IG Human IgG1κ

TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2) [Homo sapiens] Homo sapiens Abbott Laboratories (Abbott Park IL USA) (EU/US) Rheumatoid arthritis (RA) Phase M FDA approval December 2002 CHO (Chinese Hamster Ovary) cells Therapeutic Immunology FDA: (BLA) 125057

EMEA: H-C-481

ATC: L04AB04

Drugnum: 814

 [a] [j] (12) [12]
Psoriatic arthritis (PSA) Phase M FDA approval December 2002 CHO (Chinese Hamster Ovary) cells Therapeutic Immunology
BASF (Ludwigshafen Germany) / Cambridge Antibody Technology (Cambridge UK) (US) Rheumatoid arthritis (RA) Phase I/II CHO (Chinese Hamster Ovary) cells Therapeutic Immunology
164 adecatumumab 8449 90
(2004)		 52
(2004)		 MT201 IG Human IgG1

EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM) [Homo sapiens] Homo sapiens Micromet AG (Munich Germany) Breast cancers Phase II Therapeutic Oncology [p]
Prostate cancers Phase II Therapeutic Oncology
308 atorolimumab 7647 80
(1998)		 42
(1999)		 IG Human

Unknown Unknown
266 belimumab 8381 89
(2003)		 51
(2004)		 IG Human

Unknown Unknown
170 bertilimumab 8332 88
(2003)		 50
(2003)		 CAT-213,
iCo-008		 IG Human IgG4κ

CCL11 (Chemokine ligand 11; eotaxin1) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (CAT) library (Cambridge UK) iCo Therapeutics Inc. (Vancouver BC Canada) Allergies, severe ocular Phase I Therapeutic Immunology
101 blinatumomab 9028 100
(2008)		 62
(2009)		 BITE MT-103,
bscCD19xCD3,
MEDI-538/MT103		 IG Human
Murine		 scFv-scFv

CD19 (B lymphocyte surface antigen B4; Leu-12) [Homo sapiens]
CD3E (CD3 epsilon) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		Homo sapiens MedImmune Inc. (Gaithersburg MD USA) (US) B cell lymphoma Discontinued FDA Orphan drug (for indolent B cell lymphoma) January 2006 Therapeutic Oncology [p] (36)
162 briakinumab 9153 101
(2009)		 ABT-874 IG Human IgG1λ

IL12B (interleukin 12 beta; IL-12B; IL12 p40; CMLF p40; NKSF2) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (CAT) library (Cambridge UK) Abbott Laboratories (Abbott Park IL USA) Multiple sclerosis (MS) Phase I Therapeutic Immunology [p]
Crohn's disease (CD) Phase I Therapeutic Immunology
Psoriasis Phase II Therapeutic Immunology
244 canakinumab 8836 97
(2007)		 59
(2008)		 ACZ885 ILARIS® IG Human IgG1κ

IL1B (interleukin 1 beta; IL-1B) [Homo sapiens] Homo sapiens Novartis (Basel Switzerland) Rheumatoid arthritis (RA) FDA: (BLA) 125319
Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Cryopyrin-Associated Periodic Syndromes (CAPS) (including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 4 and older) Phase M FDA approval June 2009 Therapeutic Hereditary inflammatory diseases
290 cixutumumab 9099 100
(2008)		 62
(2009)		 IMC-A12 IG Human IgG1λ

IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens ImClone Systems Inc. (Somerville NJ USA) Solid tumors Phase I Therapeutic Oncology
224 conatumumab 9029 99
(2008)		 61
(2009)		 AMG 655,
TRAIL-R2mAb,
XG1-048 v w		 IG Human IgG1

TNFRSF10B (tumor necrosis factor receptor superfamily member 10B; DR5, death receptor 5; TRAIL-R2, TNF-related apoptosis-inducing ligand receptor 2; TR-2; CD262) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Cancers Phase I Therapeutic Oncology
Non-small cell lung cancers (NSCLC) Therapeutic Oncology
301 daratumumab 9128 101
(2009)		 HuMax-CD38 IG Human IgG1κ

ADP-ribosyl cyclase 1 (CD38, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10) [Homo sapiens] Genmab A/S (Copenhagen Denmark) Multiple myeloma Phase I/II Therapeutic Hematology, Oncology NCI: C74007
249 denosumab 8653 94
(2005)		 56
(2006)		 AMG162 IG Human IgG2

TNFSF11 (tumor necrosis factor ligand superfamily member 11; RANKL, receptor activator for nuclear factor kappa B ligand; human osteoclast differentiation factor) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Postmenopa osteoporosis Phase I Therapeutic Endocrinology NCI: C61313
173 efungumab 8658 95
(2006)		 57
(2007)		 HSP90mab Mycograb® IG Human scFv

Heat shock protein 90 homolog from yeast [Candida albicans] Homo sapiens NeuTec Pharma plc (Manchester UK) / Supplier: Onicon Chemical Co. Ltd. (HangZhou China) Unknown EMA refusal of marketing March 2007
262 exbivirumab 8536 91
(2004)		 53
(2005)		 IG Human

Unknown Unknown
323 fezakinumab 9137 101
(2009)		 ILV-094 IG Human IgG1λ

IL 22 (interleukin 22; IL-22) [Homo sapiens] Wyeth Pharmaceuticals (Madison NJ USA) Inflammatory conditions, acute and chronic
(Treatment)
Therapeutic Immunology
293 figitumumab 9085 100
(2008)		 62
(2009)		 CP-751871 IG Human IgG2κ

IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens 2.13.2 Pfizer (New York NY USA) Non-small cell lung cancers (NSCLC) Phase I Therapeutic Oncology NCI: C52187
Solid tumors Phase I Therapeutic Oncology
90 foravirumab 9053 99
(2008)		 61
(2009)		 CR4098 IG Human IgG1λ

Rabies virus glycoprotein [Homo sapiens] Homo sapiens Crucell (CN Leiden Netherlands) Rabies prophylaxis Phase II Therapeutic Infectiology (27)
174 fresolimumab 9158 101
(2009)		 GC-1008 IG Human IgG4κ

TGFB (Transforming Growth Factor Beta) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / Genzyme Corp. (Cambridge MA USA) Idiopathic pulmonaly fibrosis Phase I Therapeutic Pulmonary, Respiratory diseases
223 gantenerumab 8894 97
(2007)		 59
(2008)		 R1450 IG Human IgG1

Amyloid beta (A beta) peptides Aβ42 and Aβ40 [Homo sapiens] Homo sapiens F. Hoffmann-La Roche Ltd. (Basel Switzerland) Alzheimer's disease Therapeutic Neurology
175 golimumab 8497 91
(2004)		 53
(2005)		 CNTO 148 SIMPONI™ IG Human IgG1κ

TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2) [Homo sapiens] Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) Psoriatic arthritis (PSA) (fully human) Phase M FDA approval April 2009 Therapeutic Immunology FDA: (BLA) 125289
Rheumatoid arthritis (RA) Phase M FDA approval April 2009 Therapeutic Immunology
Ankylosing spondylitis (AS) Phase M FDA approval April 2009 Therapeutic Immunology
321 intetumumab 9134 101
(2009)		 CNTO 095,
CNTO-95		 IG Human IgG1κ

ITGAV/ITGB3 (INTEGRIN-ALPHA-V_BETA-3; αvβ3; CD51/CD61; CD51/GPIIIa; CD51/platelet membrane glycoprotein IIIa; VNR, vitronectin receptor; AlphaVbeta3 integrin) [Homo sapiens] Johnson & Johnson (Langhorne PA USA) Solid tumors Therapeutic Oncology
180 ipilimumab 8568 94
(2005)		 56
(2006)		 MDX-010 IG Human IgG1κ

CTLA4 [Homo sapiens] Homo sapiens Bristol-Myers Squibb (Princeton NJ USA) / Medarex (Princeton NJ USA) Melanoma Phase II/III Therapeutic Oncology NCI: C2654
250 iratumumab 8713 94
(2005)		 56
(2006)		 MDX-060 IG Human IgG1κ

TNFRSF8 (tumor necrosis factor receptor superfamily member 8; CD30) [Homo sapiens] Homo sapiens Medarex (Princeton NJ USA) Hodgkin's disease (HD) Phase II FDA Orphan drug October 2004 Therapeutic Hematology, Oncology
Anaplastic large cell lymphoma (ALCL) Phase II Therapeutic Oncology
182 lerdelimumab 7882 83
(2000)		 45
(2001)		 CAT-152,
Trabio		 IG Human IgG4

TGFB2 (transforming growth factor beta 2) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (CAT) library (Cambridge UK) Cambridge Antibody Technology (Cambridge UK) Glaucoma surgery Phase III Therapeutic Ophthalmology [a] [12]
183 lexatumumab 8753 95
(2006)		 57
(2007)		 HGS-ETR2 IG Human IgG1λ

TNFRSF10B (tumor necrosis factor receptor superfamily member 10B; DR5, death receptor 5; TRAIL-R2, TNF-related apoptosis-inducing ligand receptor 2; TR-2; CD262) [Homo sapiens] Homo sapiens HGSI (Human Genome Sciences Inc.) (Rockville MD USA) Cancers Phase I Therapeutic Oncology NCI: C64621

 [p]
263 libivirumab 8481 91
(2004)		 53
(2005)		 IG Human

Unknown Unknown
176 lucatumumab 8887 98
(2007)		 60
(2008)		 CHIR-12,12,
HCD122		 IG Human IgG1

CD40 (tumor necrosis factor receptor superfamily member 5; TNFRSF5) [Homo sapiens] Homo sapiens Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Xoma (Berkeley CA USA) Multiple myeloma Phase I Therapeutic Hematology, Oncology [p]
Chronic lymphocytic leukemia (CLL) Phase I Therapeutic Oncology
184 mapatumumab 8635 93
(2005)		 55
(2006)		 HGS-ETR1,
TRM-1		 IG Human IgG1

TRAIL-R1 (Tumor necrosis apoprosis Inducing ligand Receptor 1), agonistic antibody [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / HGSI (Human Genome Sciences Inc.) (Rockville MD USA) Lung cancers, Lung cancers (non small-cell) Phase II Therapeutic Oncology NCI: C61502
Colorectal cancers Phase II Therapeutic Oncology
Non-Hodgkin's lymphoma (NHL) Phase II Therapeutic Oncology
186 metelimumab 8087 86
(2002)		 48
(2002)		 CAT-192 IG Human IgG4κ

TGF-1 (Transforming Growth Factor 1) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (CAT) library (Cambridge UK) Cambridge Antibody Technology (Cambridge UK) / Genzyme Corp. (Cambridge MA USA) Diffuse scleroderma Phase I/II Therapeutic Dermatology [12]
Scarring Phase I/II Therapeutic Dermatology
Fibrotic diseases Phase I/II Therapeutic Dermatology
311 morolimumab 7646 79
(1998)		 41
(1999)		 IG Human

Unknown Unknown
193 nebacumab 6658 66
(1991)		 32
(1992)		 centoxin,
HA-1A,
septomonab		 IG Human IgM

Endotoxin C0246612 [Homo sapiens] Homo sapiens CSL Behring (King of Prussia PA USA) Gram-negative sepsis Therapeutic Infectiology
294 necitumumab 9083 100
(2008)		 62
(2009)		 11F8,
IMC-11F8		 IG Human IgG1κ

EGFR (Epidermal Growth Factor Receptor; ERBB1; HER1; ERBB) [Homo sapiens] Homo sapiens ImClone Systems Inc. (Somerville NJ USA) Colorectal cancers, metastatic Phase II Therapeutic Oncology
Solid tumors Phase I Therapeutic Oncology
194 ofatumumab 8606 93
(2005)		 55
(2006)		 HuMax-CD20® Arzerra™ IG Human IgG1κ

MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / GlaxoSmithKline (Brentford UK) Non-Hodgkin's lymphoma (NHL) Withdrawn withdrawal (by manufacture) January 1993 Therapeutic Oncology NCI: C66952
Chronic lymphocytic leukemia (CLL) (Refractory) Phase III SBLA April 2009 Therapeutic Oncology
Rheumatoid arthritis (RA) Phase III Therapeutic Immunology
196 panitumumab 8499 91
(2004)		 53
(2005)		 ABX-EGF,
E7.6.3		 VECTIBIX™ IG Human IgG2κ

EGFR (Epidermal Growth Factor Receptor; ERBB1; HER1; ERBB) [Homo sapiens] Homo sapiens XenoMouse (Abgenix/ Fremont CA USA) Amgen (Thousand Oaks CA USA) Neck cancers Phase III CHO (Chinese Hamster Ovary) cells Therapeutic Oncology FDA: (BLA) 125147

NCI: C1857

Drugnum: 933

 [b] [n] (11) (13)
Colorectal cancers Phase III CHO (Chinese Hamster Ovary) cells Therapeutic Oncology
Colorectal cancers, metastatic Phase M FDA approval September 2006 CHO (Chinese Hamster Ovary) cells Therapeutic Oncology
Head cancers Phase III CHO (Chinese Hamster Ovary) cells Therapeutic Oncology
243 panobacumab 8888 100
(2008)		 62
(2009)		 Aerumab 11 IG Human IgMκ

Pseudomonas aeruginosa serotype IATS O11 [bacteria] Homo sapiens Kenta Biotech Ltd (Berne Switzerland) Pseudomonas aeruginosa, hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa
(Treatment)
Phase I Therapeutic Infectiology
270 pritumumab 8132 89
(2003)		 51
(2004)		 IG Human

Unknown Unknown
94 rafivirumab 9052 99
(2008)		 61
(2009)		 CR57 IG Human IgG1

Rabies virus glycoprotein [Homo sapiens] Homo sapiens Crucell (CN Leiden Netherlands) Rabies prophylaxis Phase II Therapeutic Immunology (27)
295 ramucirumab 9098 100
(2008)		 62
(2009)		 1121B,
IMC-1121B		 IG Human IgG1κ

KDR (kinase insert domain receptor; VEGFR2, Vascular endothelial growth factor receptor 2; VEGF-R2; FLK1; CD309) [Homo sapiens] Homo sapiens ImClone Systems Inc. (Somerville NJ USA) Tumor vasculature Phase I Therapeutic Oncology [p]
260 raxibacumab 8580 92
(2004)		 54
(2005)		 IG Human

Unknown Unknown
197 regavirumab 7250 71
(1994)		 35
(1995)		 TI-23 IG Human IgG1κ

Herpesvirus 5 glyco-protein B [Homo sapiens] Homo sapiens Teijin America Inc. (New York NY USA) / Teijin Ltd. (Tokyo Japan) Cytomegalovirus (CMV) diseases, acute Phase I Therapeutic Infectiology [e]
302 rilotumumab 9123 101
(2009)		 IG Human IgG2

Hepatocyte growth factor (HGF, scatter factor, SF, hepatopoeitin A) [Homo sapiens] Amgen (Thousand Oaks CA USA) Cancers Phase II Therapeutic Oncology
296 robatumumab 9092 100
(2008)		 62
(2009)		 19D12,
SCH 717454,
SCH717454		 IG Human IgG1κ

IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens Medarex (Princeton NJ USA) Blood cancers Preclinical Therapeutic Oncology
Colon sarcoma Phase II Therapeutic Oncology
326 secukinumab 9182 101
(2009)		 AIN457 IG Human IgG1κ

IL17A (interleukin 17A; IL-17A) [Homo sapiens] Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Psoriasis Phase III Therapeutic Immunology
319 sevirumab 6560 66
(1991)		 32
(1992)		 IG Human

Unknown Unknown
322 sifalimumab 9135 101
(2009)		 MDX-1103,
MEDI-545		 IG Human IgG1κ

IFNA (IFN alpha; interferon alpha) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Polymyositis
(Treatment)
Therapeutic Immunology
Dermatomyositis
(Treatment)
Therapeutic Immunology
Systemic lupus erythematosus (SLE)
(Treatment)
Therapeutic Immunology
192 stamulumab 8683 94
(2005)		 56
(2006)		 MYO-029 IG Human IgG1

GDF-8 (growth differentiation factor 8) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (Cambridge UK) / Wyeth Pharmaceuticals (Madison NJ USA) Muscular dystrophy Phase I/II Therapeutic Myology
336 teprotumumab 9107 101
(2009)		 IG Human IgG1

IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Unknown Unknown
171 tralokinumab 9235 102
(2009)		 CAT-354 IG Human IgG1λ

IL13 (interleukin 13; IL-13) [Homo sapiens] Homo sapiens Cambridge Antibody Technology (CAT) library (Cambridge UK) MedImmune Inc. (Gaithersburg MD USA) Asthma, severe
(Treatment)
Phase II Therapeutic Immunology
248 tremelimumab 8716 94
(2005)		 59
(2008)		 CP-675206 IG Human IgG2

CTLA4 [Homo sapiens] Homo sapiens 11.2.1 Abgenix (Fremont CA USA) / Pfizer (New York NY USA) Melanoma Therapeutic Oncology NCI: C49085
169 tuvirumab 6559 66
(1991)		 32
(1992)		 anti-hepatitis B IG Human

HBV (hepatitis B virus) [virus] Homo sapiens PDL (Protein Design Labs) BioPharma (Fremont CA USA) Hepatitis B (Chronic active) Phase II Therapeutic Infectiology [e]
Hepatitis B, chronic infection causing end-stage renal disease in liver transplant patients Phase I/II Therapeutic Infectiology
172 ustekinumab 8954 99
(2008)		 61
(2009)		 CNTO 1275,
TT-20		 STELARA™ IG Human IgG1

IL12 (interleukin 12; IL-12) [Homo sapiens]
IL23 (interleukin 23; IL-23) [Homo sapiens] 		Homo sapiens Centocor Ortho Biotech Inc. (Horsham PA USA) / Medarex (Princeton NJ USA) Psoriasis Phase M FDA approval September 2009, EMA approval January 2009 Therapeutic Immunology FDA: (BLA) 125261

EMEA: H-C-958
Inflammation Phase III Therapeutic Immunology
Crohn's disease (CD) Phase III Therapeutic Immunology
Multiple sclerosis (MS) Phase II Therapeutic Immunology
199 votumumab 7165 70
(1993)		 34
(1994)		 Technetium (99mTc) votumumab HumaSPECT® IG Human IgG3κ

radiolabelled with Technetium-99m, Tc-99m		 CTAA16.88 Carcinoma associated antigen [Homo sapiens] Homo sapiens 88-BV59 KS Biomedix Ltd (Guildford UK) / Organon Teknika Corp. (Durham NC USA) Colon cancers Withdrawn EC withdrawal (Not renewed by KS Biomedix) September 2003, EC approval September 1998 Therapeutic Oncology [d] (31) (39)
Rectum cancers Withdrawn EC withdrawal (Not renewed by KS Biomedix) September 2003, EC approval September 1998 Therapeutic Oncology
200 zalutumumab 8605 93
(2005)		 55
(2006)		 HuMax-EGFr HuMaX-EGFR™ IG Human IgG1κ

EGFR (Epidermal Growth Factor Receptor; ERBB1; HER1; ERBB) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) Head cancers Phase III Therapeutic Oncology NCI: C64620
Neck cancers Phase III Therapeutic Oncology
201 zanolimumab 8298 90
(2004)		 52
(2004)		 HuMax-CD4 HuMax-CD4® IG Human IgG1κ

CD4 (p55) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Non-cutaneous T cell lymphoma (NCTCL) Phase II Therapeutic Oncology
Cutaneous T cell lymphoma (CTCL) Phase III Therapeutic Oncology
8 ziralimumab 8061 84
(2000)		 46
(2001)		 ABX-RB2 IG Human IgM

BSG (Basigin; CD147) [Homo sapiens] Homo sapiens XenoMouse (Abgenix/ Fremont CA USA) Abgenix (Fremont CA USA) Solid organ transplantation Preclinical
Autoimmune diseases Preclinical Therapeutic Immunology
Graft-versus-host disease (GvHD) Preclinical
99 4D5 and UCHT1,
trastuzumab coupled with UCHT1 F(ab')2		 IG Human
Murine		 F(ab')2, chemically coupled with 4D5 (trastuzumab)

CD3E (CD3 epsilon) [Homo sapiens]
ERBB2 (Epidermal Growth Factor Receptor 2; HER-2; p185c-erbB2; NEU; EGFR2) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		Mus musculus Charing Cross Sunley Research Centre (UK) / Genentech Inc. (S. San Francisco CA USA) / ICRF (UK) Cancers (overexpressing ERBB2) Adenovirus transformed human embryonic 293 kidney cells [c] (36) [42]
163 ABX-IL8 IG Human IgG2

IL8 (interleukin 8; IL-8) [Homo sapiens] Homo sapiens Abgenix (Fremont CA USA) Rheumatoid arthritis (RA) Phase II [a] [b] (11)
Angiogenesis Preclinical
Melanoma Preclinical
Psoriasis Phase II
166 AGS-PSCA,
MK-4721		 IG Human IgG1κ

PSCA (prostate stem cell antigen) [Homo sapiens] Homo sapiens XenoMouse (Abgenix/ Fremont CA USA) Agensys (Santa Monica CA USA) / Merck & Co., Inc. (Whitehouse Station NJ USA) Bladder cancers Phase I [p]
Prostate cancers Phase I
Pancreatic cancers Phase I
167 AL-901 Human

IgE [Homo sapiens] Homo sapiens Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA) Allergic asthma Phase II [e]
Allergic rhinitis Phase II
168 AMG 479 Human

IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Homo sapiens Amgen (Thousand Oaks CA USA) Cancers Phase I [p]
177 HuMax-IL15 Human

Il15 (interleukin 15; IL-15) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / Immunex Corporation Amgen (Thousand Oaks CA USA) Psoriasis Phase I/II
Inflammatory bowel disease (IBD) Phase I/II
Celiac disease Phase I/II
Inflammatory arthritis diseases Phase I/II
178 HuMax-Lymphoma Human

IL15R (interleukin 15 receptor; IL-15R) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) / Immunex Corporation Amgen (Thousand Oaks CA USA) Lymphoma Preclinical
228 HuMax-TAC™ Human

IL2RA (interleukin-2 receptor, alpha subunit; IL-2RA; TAC; CD25) [Homo sapiens] Homo sapiens Genmab A/S (Copenhagen Denmark) Autoimmune disorders Preclinical
Transplant rejection Preclinical
181 J695 Human

IL12 (interleukin 12; IL-12) [Homo sapiens] Homo sapiens BASF (Ludwigshafen Germany) / Cambridge Antibody Technology (Cambridge UK) (US) Multiple sclerosis (MS) [12]
Rheumatoid arthritis (RA)
Crohn's disease (CD)
185 MDX-33 Human

FCGR1 (FCGR1A, FCGR1B, FCGR1C) (Fc gamma RI; CD64) [Homo sapiens] Homo sapiens CSL Behring (King of Prussia PA USA) / Medarex (Princeton NJ USA) Idiopathic thrombocytopenic purpura Phase I [a] [b]
Autoimmune diseases Phase I
187 MOR101 IG Human Fab

CD54 (intercellular adhesion molecule 1; ICAM1) [Homo sapiens] Homo sapiens MorphoSys (Martinsried/Pla Germany) Deep dermal burn Preclinical [n] (22)
188 MOR102 IG Human IgG4 Fab

CD54 (intercellular adhesion molecule 1; ICAM1) [Homo sapiens] Homo sapiens MorphoSys (Martinsried/Pla Germany) Psoriasis Preclinical [n] (22)
189 MOR103 Human

Homo sapiens MorphoSys (Martinsried/Pla Germany) Rheumatoid arthritis (RA) Phase I [n] (22)
190 MOR202 IG Human IgG1

CD38 [Homo sapiens] Homo sapiens MorphoSys (Martinsried/Pla Germany) Multiple myeloma Preclinical Therapeutic Hematology, Oncology [n] (22)
64 MORAb-009 IG Human IgG1

Morphotek Inc. (Exton PA USA) Pancreatic cancers Phase II EC Orphan drug April 2008
191 MORAb-028 IG Human IgM

G-28, a cell surface antigen glycolipid [Homo sapiens] Homo sapiens CMC Biopharmaceuticals (Copenhagen Denmark) / Morphotek Inc. (Exton PA USA) Melanoma [p]
195 OST 577 OSTAVIR™ Human

HBV (hepatitis B virus) [virus] Homo sapiens Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Hepatitis B Phase II [a]

up

Rat

Number of results: 3

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT/mAb-DB receptor type IMGT/mAb-DB species Isotype and format Conjugated/ Radiolabelled Specificity target name
[species]		 Origin clone species Origin clone name Company Clinical indication Development status Regulatory agency status and year Expression Application Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
218 catumaxomab 8406 93
(2005)		 55
(2006)		 Removab® IG Rat
Murine		 IgG2a (Ho-3/TP-A-01/TPBs01) [Mus musculus]
IgG2b (26/II/6-1.2/TPBs01) [Rattus sp.]

CD3E (CD3 epsilon) [Homo sapiens]
EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		rat-murine hybrid (triomab?) Fresenius Biotech GmbH (Bad Homburg Germany) Malignant ascites Phase II/III EC Orphan drug November 2006 Therapeutic Oncology [o] (28) (36)
Ovarian cancers Phase II/III EC Orphan drug November 2006 Therapeutic Oncology
Gastric cancers Phase II/III EC Orphan drug November 2006 Therapeutic Oncology
219 ertumaxomab 8407 93
(2005)		 55
(2006)		 Rexomun® IG Rat
Murine		 IgG2a (2502A/TP-A-02/TPBs03) [Mus musculus]
IgG2b (26/II/6-1.2/TPBs01) [Rattus sp.]

CD3E (CD3 epsilon) [Homo sapiens]
ERBB2 (Epidermal Growth Factor Receptor 2; HER-2; p185c-erbB2; NEU; EGFR2) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		rat-murine hybrid (triomab?) Fresenius Biotech GmbH (Bad Homburg Germany) Breast cancers Phase II Therapeutic Oncology [o] (28) (36)
107 BT1-322 IG Rat IgG2b

Rattus sp. BioTransplant (Charlestown MA USA) / MedImmune Inc. (Gaithersburg MD USA) Graft-versus-host disease (GvHD) Phase I/II [e] [n] [62]
Acute kidney transplant rejection Phase I/II

up

Murine

Number of results: 65

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT/mAb-DB receptor type IMGT/mAb-DB species Isotype and format Conjugated/ Radiolabelled Specificity target name
[species]		 Origin clone species Origin clone name Company Clinical indication Development status Regulatory agency status and year Expression Application Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
111 abagovomab 8659 95
(2006)		 57
(2007)		 ACA125,
MEN-2234		 IG Murine IgG1κ

MUC16 (CA125, Homo sapiens cancer antigen 125; MUC-16; Mus musculus mAb OC125)Paratope of anti-, (idiotope) [Homo sapiens] Mus musculus 3D5 Menarini (Florence Italy) Ovarian cancers Phase III Therapeutic Oncology
315 afelimomab 7340 72
(1994)		 35
(1995)		 IG Murine

Unknown Unknown
312 altumomab 7046 68
(1992)		 33
(1993)		 IG Murine

Unknown Unknown
287 anatumomab mafenatox 7655 79
(1998)		 41
(1999)		 IG Murine

Unknown Unknown
113 arcitumomab 7417 74
(1995)		 36
(1996)		 CEA-Scan CEA-SCAN™ IG Murine IgG1 Fab'

radiolabelled with Technetium-99m, Tc-99m		 CEACAM5 (carcinoembryonic antigen; CEA; CD66e) [Homo sapiens] Mus musculus NP4, IMMU-4 Immunomedics Inc. (Morris Plains NJ USA) Lung cancers Phase III [b] [n] (31)
Breast cancers Phase II
Colorectal cancers (radiodiagnostic imaging of tumors) Withdrawn EC withdrawal (on holders request) November 2005, EC approval October 1996, FDA approval June 1996 Murine ascites, pepsin digestion Diagnostic Oncology
306 bectumomab 7514 75
(1996)		 37
(1997)		 IG Murine

Unknown Unknown
258 besilesomab 8451 92
(2004)		 54
(2005)		 IG Murine

Unknown Unknown
131 biciromab 6867 66
(1991)		 32
(1992)		 Indium (111In) biciromab FibriScint™ IG Murine Fab'

radiolabelled with Indium-111, In-111		 Fibrin II [Homo sapiens] Mus musculus T2G1 Centocor Inc. (Horsham PA USA) Cardiovascular thrombosis (in vivo imaging agent) Withdrawn FDA withdrawal (PLA withdrawal, on holders request) June 1993 Diagnostic Cardiology [b] (31)
101 blinatumomab 9028 100
(2008)		 62
(2009)		 BITE MT-103,
bscCD19xCD3,
MEDI-538/MT103		 IG Human
Murine		 scFv-scFv

CD19 (B lymphocyte surface antigen B4; Leu-12) [Homo sapiens]
CD3E (CD3 epsilon) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		Homo sapiens MedImmune Inc. (Gaithersburg MD USA) (US) B cell lymphoma Discontinued FDA Orphan drug (for indolent B cell lymphoma) January 2006 Therapeutic Oncology [p] (36)
115 capromab 7201 70
(1993)		 34
(1994)		 7E11-C5.3,
pendetide		 PROSTASCINT® IG Murine IgG1κ

radiolabelled with Indium-111, In-111		 PSMA (prostate specific membrane antigen) [Homo sapiens] Mus musculus EUSA Pharma (Doylestown PA USA) Prostate cancers Phase M FDA approval October 1996 Diagnostic Oncology FDA: (BLA) 103608

 [b] [d] [n] (31)
218 catumaxomab 8406 93
(2005)		 55
(2006)		 Removab® IG Rat
Murine		 IgG2a (Ho-3/TP-A-01/TPBs01) [Mus musculus]
IgG2b (26/II/6-1.2/TPBs01) [Rattus sp.]

CD3E (CD3 epsilon) [Homo sapiens]
EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		rat-murine hybrid (triomab?) Fresenius Biotech GmbH (Bad Homburg Germany) Malignant ascites Phase II/III EC Orphan drug November 2006 Therapeutic Oncology [o] (28) (36)
Ovarian cancers Phase II/III EC Orphan drug November 2006 Therapeutic Oncology
Gastric cancers Phase II/III EC Orphan drug November 2006 Therapeutic Oncology
313 detumomab 7156 70
(1993)		 34
(1994)		 IG Murine

Unknown Unknown
207 dorlimomab aritox 6516 66
(1991)		 32
(1992)		 4197X-RA,
MDX-RA (Ricin A)		 IG Murine

Houston Biotechnology (The Woodlands TX USA) / Medarex (Princeton NJ USA) Secondary cataract, Secondary cataract
(Prevention)
Phase III Therapeutic Ophthalmology [b] [e] (29)
118 edobacomab 7056 69
(1993)		 34
(1994)		 E5™ IG Murine IgM

Endotoxin C0246612 [Homo sapiens] Mus musculus Pfizer (New York NY USA) / Xoma (Berkeley CA USA) Gram-negative sepsis Phase III Therapeutic Infectiology [e]
119 edrecolomab 7471 74
(1995)		 36
(1996)		 17-1A PANOREX® IG Murine IgG2a

EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Colon cancers Phase M approval (Germany) January 1995 Sp2/0 mouse myeloma cells Therapeutic Oncology NCI: C1554

 [a] [e]
268 elsilimomab 8371 89
(2003)		 51
(2004)		 IG Murine

Unknown Unknown
120 enlimomab 6964 70
(1993)		 34
(1994)		 BIRR-1 IG Murine IgG2a

CD54 (intercellular adhesion molecule 1; ICAM1) [Homo sapiens] Mus musculus Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) Stroke Phase II/III Therapeutic Cardiology [a] [e]
Thermal injury Phase II Therapeutic Hematology
317 enlimomab pegol 7525 77
(1997)		 39
(1998)		 IG Murine

Mus musculus Unknown Unknown
303 epitumomab 7833 82
(1999)		 44
(2000)		 IG Murine

Unknown Unknown
269 epitumomab cituxetan 8372 89
(2003)		 51
(2004)		 IG Murine IgG1κ conjugated wih chelator cituxetan

radiolabelled with Yttrium-90, Y-90		 MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin, episialin) [Homo sapiens] Mus musculus HMFG-1 Unknown Epithelial Ovarian cancers Phase III Therapeutic Oncology
219 ertumaxomab 8407 93
(2005)		 55
(2006)		 Rexomun® IG Rat
Murine		 IgG2a (2502A/TP-A-02/TPBs03) [Mus musculus]
IgG2b (26/II/6-1.2/TPBs01) [Rattus sp.]

CD3E (CD3 epsilon) [Homo sapiens]
ERBB2 (Epidermal Growth Factor Receptor 2; HER-2; p185c-erbB2; NEU; EGFR2) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		rat-murine hybrid (triomab?) Fresenius Biotech GmbH (Bad Homburg Germany) Breast cancers Phase II Therapeutic Oncology [o] (28) (36)
305 faralimomab 7496 76
(1996)		 38
(1997)		 IG Murine

Unknown Unknown
112 gavilimomab 8060 84
(2000)		 46
(2001)		 ABX-CBL IG Murine IgM

CD147 [Homo sapiens] Mus musculus Abgenix (Fremont CA USA) Allograft rejection Phase II Therapeutic Immunology [a] [b] [52]
Graft-versus-host disease (GvHD) (steroid-refractory) Phase III Therapeutic Immunology
122 ibritumomab tiuxetan 7873 81
(1999)		 43
(2000)		 In-111 Zevalin,
Y-90 Zevalin		 ZEVALIN® IG Murine IgG1κ conjugated with chelator tiuxetan

radiolabelled with Yttrium-90, Y-90 (Therapeutic) and Indium-111, In-111 (Diagnostic)		 MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35) [Homo sapiens] Mus musculus IDEC-Y2B8 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Schering AG (Berlin Germany) Non-Hodgkin's lymphoma (NHL) Phase M FDA approval February 2002 CHO (Chinese Hamster Ovary) cells Diagnostic, Therapeutic Oncology [j] [n] (31)
123 igovomab 7433 77
(1997)		 39
(1998)		 Indimacis 125,
OC125 chelator DTPA		 IG Murine IgG1 F(ab')2

radiolabelled with Indium-111, In-111		 Tumor associated antigen CA125 [Homo sapiens] Mus musculus CIS Bio international (Bagnols/C France) Ovarian cancers Withdrawn EC withdrawal (on holders request) September 1999, FDA approval September 1996 Diagnostic Oncology [d] [n] (31)
124 imciromab 6605 66
(1991)		 32
(1992)		 R1D10 pentetate MYOSCINT® IG Murine IgG2aκ Fab

radiolabelled with Indium-111, In-111		 Cardiac myosin [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / Eli Lilly (Indianapolis IN USA) Myocardial infarction (imaging agent) Withdrawn FDA withdrawal (too expensive to manufacture) February 1999, FDA approval July 1996 Murine ascites, pepsin digestion Diagnostic Cardiology FDA: (BLA) 103634

 [b] [d] [n] (31)
126 inolimomab 7253 71
(1994)		 35
(1995)		 IG Murine

IL2RA (interleukin-2 receptor, alpha subunit; IL-2RA; TAC; CD25) [Homo sapiens] Mus musculus OPI (Orphan Pharma International) (Dardilly France) Graft versus-host disease (GvHD), acute Phase II/III Therapeutic Immunology
281 lemalesomab 8046 84
(2000)		 46
(2001)		 IG Murine

Unknown Unknown
318 maslirnomab 6614 66
(1991)		 32
(1992)		 IG Murine

Unknown Unknown
309 minretumomab 7821 80
(1998)		 42
(1999)		 IG Murine

Unknown Unknown
130 mitumomab 7934 82
(1999)		 44
(2000)		 BEC2 IG Murine IgG

GD3 idiotype [Homo sapiens] Mus musculus ImClone Systems Inc. (Somerville NJ USA) / Memorial Sloan-Kettering Cancer Center (New York NY USA) / Merck KgaA (Darmstadt Germany) Cancers Phase III Therapeutic Oncology [a] [e] (9)
Small cell lung cancers (SCLC) Phase III Therapeutic Oncology
Melanoma Phase III Therapeutic Oncology
198 moxetumomab pasudotox 9236 102
(2009)		 CAT-8015,
GCR-8015,
HA22		 IG Murine disulfide stabilized Fv fragment [Mus musculus] conjugated with Pseudomonas aeruginosa exotoxin A

 CD22 (BL-CAM)
CD22 (sialic acid-binding Ig-like lectin2, Siglec-2, SIGLEC2, Leu14, B-lymphocyte cell adhesion molecule, BL-CAM) [Homo sapiens] 		MedImmune Inc. (Gaithersburg MD USA) Acute lymphocytic leukemia (ALL) Phase I Therapeutic Hematology, Oncology NCI: C68819

 (29)
Chronic lymphocytic leukemia (CLL) Phase I Therapeutic Hematology, Oncology
Hairy cell Leukemia (HCL) Phase I Therapeutic Hematology, Oncology
132 muromonab-CD3 6281 59
(1988)		 29
(1989)		 OKT3 ORTHOCLONE OKT3® IG Murine IgG2a

CD3E (CD3 epsilon) [Homo sapiens] Mus musculus Ortho Biotech Products LP (Bridgewater NJ USA) Heart transplant rejection (reversal) Phase M FDA approval September 1992 Murine ascites, hybridoma Therapeutic Immunology FDA: (BLA) 103463

NCI: C1321

 [a] [b] [d] [j] [n]
Acute kidney transplant rejection (reversal) Phase M FDA approval September 1992 Murine ascites, hybridoma Therapeutic Immunology
Liver transplantation (reversal) Phase M FDA approval September 1992 Murine ascites, hybridoma Therapeutic Immunology
316 nacolomab tafenatox 7227 71
(1994)		 35
(1995)		 IG Murine

Unknown Unknown
65 naptumomab estafenatox 8598 96
(2006)		 58
(2007)		 ABR-217620,
ANYARA,
TTS CD3		 IG Murine IgG1κ Fab superantigen conjugated with Staphyloccocus aureus enterotoxin E SEA/E120 (synthetic)

 TPBG (trophoblast glycoprotein; 5T4) [Homo sapiens] Mus musculus 5T4 Active Biotech AB (Lund Sweden) Renal cell carcinoma (RCC) Therapeutic Oncology (29)
Non-small lung carcinomia Therapeutic Oncology
307 nerelimomab 7546 76
(1996)		 38
(1997)		 IG Murine

Unknown Unknown
134 odulimomab 7364 73
(1995)		 36
(1996)		 afolimomab,
anti-LFA1		 ANTILFA® IG Murine IgG1 F(ab')2

ITGAL (INTEGRIN-ALPHA-L; LFA-1, lymphocyte function associated antigen 1; CD11a) [Homo sapiens] Mus musculus 25.3 Pasteur M (Lyon France) Allograft rejection Phase III not renewed April 2000, ATU (Temporary Authorizations for Use) August 1994 Therapeutic Immunology [a] [n]
136 oregovomab 8183 86
(2002)		 48
(2002)		 MAB-B43.13,
oregovamab		 OVAREX® IG Murine IgG1κ

Tumor associated antigen CA125 [Homo sapiens] Mus musculus B43.13 AltaRex Corp. (Edmonton AB Canada) Ovarian cancers Phase II Therapeutic Oncology NCI: C1784

 [a]
225 racotumomab 8998 100
(2008)		 62
(2009)		 1E10 IG Murine IgG1κ

Paratope of anti-(N-glycolylneuraminic acid (NeuGc, NGNA)-gangliosides GM3) Mus musculus IgM-kappa P3, (idiotope) [Homo sapiens] Mus musculus CMI (Center of Molecular Immunology) (Playa Cuba) Breast cancers Preclinical Therapeutic Oncology
Melanoma Preclinical Therapeutic Oncology
138 satumomab 6977 68
(1992)		 33
(1993)		 Indium (111In) satumomab pendetide ONCOSCINT®, OncoScint CR/OV, OncoScint CR103 IG Murine IgG1κ

radiolabelled with Indium-111, In-111		 TAG 72 (tumour associated glycoprotein 72) [Homo sapiens] Mus musculus B72.3 Cytogen Corp. (Princeton NJ USA) / Lonza Biologics (Basel Switzerland) Colorectal cancers Withdrawn FDA approval December 1992 Diagnostic Oncology [b] [n] (31) (38)
Ovarian cancers Withdrawn FDA approval December 1992 Diagnostic Oncology
139 sulesomab 7519 75
(1996)		 37
(1997)		 Technetium (99mTc) sulesomab, LeukoScan LEUKOSCAN® IG Murine IgG1 Fab'

radiolabelled with Technetium-99m, Tc-99m		 NCA-90 (granulocyte cell antigen 10) [Homo sapiens] Mus musculus IMMU-MN3 Immunomedics Inc. (Morris Plains NJ USA) Acute atypical appendicitis Therapeutic Hereditary inflammatory diseases [b] [d] (10) (31)
Inflammatory bowel disease (IBD) Phase II Therapeutic Hereditary inflammatory diseases
Osteomyelitis Therapeutic Immunology
282 taplitumomab paptox 8047 84
(2000)		 46
(2001)		 IG Murine IgG1κ conjugated with Phytolacca americana (pokeweed) antiviral protein PAP

 CD19 (B lymphocyte surface antigen B4; Leu-12) [Homo sapiens] B43 Unknown Cancers Therapeutic Oncology
140 technetium (99mTc) fanolesomab 8150 86
(2002)		 48
(2002)		 IG Murine IgM

radiolabelled with Technetium-99m, Tc-99m		 CD15 [Homo sapiens] Mus musculus RB5 Palatin Technologies Inc. (Cranbury NJ USA) Appendicitis (Radionuclide imaging) Withdrawn FDA withdrawal (life-threatening adverse events) December 2005, FDA approval July 2004 Therapeutic Hereditary inflammatory diseases [j] (31)
133 technetium (99mTc) nofetumomab merpentan 7542 76
(1996)		 38
(1997)		 VERLUMA® IG Murine IgG2bk Fab conjugated wih chelator DTPA

radiolabelled with Technetium-99m, Tc-99m		 MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35) [Homo sapiens] Mus musculus NR-LU-10 Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) / DuPont Merck Pharmaceutical (Billerica MA USA) / NeoRx Corp. (Seattle WA USA) Small cell lung cancers (SCLC) Withdrawn FDA approval August 1996 Diagnostic Oncology [b] [d] [n] (31)
286 technetium (99mTc) pintumomab 7513 75
(1996)		 37
(1997)		 IG Murine IgG1κ

radiolabelled with Technetium-99m, Tc-99m		 Adenocarcinoma antigen [Homo sapiens] Mus musculus 170 Unknown Adenocarcinoma Diagnostic Oncology (31)
320 telimomab aritox 6345 66
(1991)		 32
(1992)		 T101-ricin A chain immunotoxin, T101-RTA IG Murine Fab conjugated with ricin A

 anti-CD5 [Homo sapiens] Mus musculus T101 Unknown Chronic lymphocytic leukemia (CLL) Phase I Discontinued Therapeutic Hematology, Oncology
226 tenatumomab 8832 98
(2007)		 60
(2008)		 ST2146 IG Murine IgG2b

TNC (Tenascin C; HBX, hexabrachion) [Homo sapiens] Mus musculus SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (Pomezia Italy) Cancers Therapeutic Oncology
142 tositumomab 7827 80
(1998)		 42
(1999)		 BEXXAR® IG Murine IgG2a

radiolabelled with Iodine-131, I-131		 MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35) [Homo sapiens] Mus musculus Corixa Corp. (Seattle WA USA) / GlaxoSmithKline (Brentford UK) Non-Hodgkin's lymphoma (NHL) (Follicular CD20 positive, following chemotherapy relapse) Phase M FDA approval June 2003 Hybridoma Therapeutic Oncology FDA: (BLA) 125011

NCI: C2543

Drugnum: 834

 [j] [n] (31)
310 vepalimomab 7757 80
(1998)		 42
(1999)		 IG Murine

Unknown Unknown
314 zolimomab aritox 7055 69
(1993)		 34
(1994)		 H65-ricin A chain immunotoxin, H65-RTA IG Murine conjugated with ricin A

 anti-CD5 [Homo sapiens] Mus musculus H65 Unknown Cutaneous T cell lymphoma (CTCL) Phase I Discontinued Therapeutic Oncology
Graft-versus-host disease (GvHD) Phase I Discontinued Therapeutic Immunology
Systemic lupus erythematosus (SLE) Phase I Discontinued Therapeutic Immunology
108 14F7 IG Murine IgG1

IRP-2 (Iron Regulatory Protein 2) [Homo sapiens] Mus musculus Centre of Molecular Immunology (Havana Cuba) Unknown [p]
109 14G2a IG Murine IgG2a

GD2 ganglioside [Homo sapiens] Mus musculus National Cancer Institute (Bethesda MD USA) Melanoma Phase I [e]
Solid tumors Phase I
110 177 Lu-J591,
HuJ591-GS		 Murine

radiolabelled with Lutetium-177, Lu-177		 PSMA (prostate specific membrane antigen) [Homo sapiens] Mus musculus Weill Cornell Medical (New York NY USA) Prostate cancers, metastatic (androgen-Independent) Phase I/II Therapeutic Oncology (23) (31) (37)
141 225.28S,
Tecnemab-K-1		 IG Murine F(ab')2, Fab/Fab2 mix conjugated wih chelator DTPA

radiolabelled with Technetium-99m, Tc-99m		 HMW-MAA (High molecular weight-melanoma-associated antigen) [Homo sapiens] Mus musculus Sorin Radiofarmaci S.R.L. (Milan Italy) Cutaneous melanoma lesions Withdrawn EC withdrawal (on holders request) February 2000, EC approval April 1997, FDA approval September 1996 [d] [n] (31)
99 4D5 and UCHT1,
trastuzumab coupled with UCHT1 F(ab')2		 IG Human
Murine		 F(ab')2, chemically coupled with 4D5 (trastuzumab)

CD3E (CD3 epsilon) [Homo sapiens]
ERBB2 (Epidermal Growth Factor Receptor 2; HER-2; p185c-erbB2; NEU; EGFR2) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		Mus musculus Charing Cross Sunley Research Centre (UK) / Genentech Inc. (S. San Francisco CA USA) / ICRF (UK) Cancers (overexpressing ERBB2) Adenovirus transformed human embryonic 293 kidney cells [c] (36) [42]
116 COL-1 Murine

CEACAM3, CGM1 [Homo sapiens] Mus musculus National Cancer Institute (Bethesda MD USA) Colorectal cancers Phase I [e]
Gastric cancers Phase I
117 CYT-356-Y-90 ONCOLTAD® Murine

Mus musculus Cytogen Corp. (Princeton NJ USA) Prostate cancers (targeted radiotherapy) Phase II [e]
121 HNK20 IG Murine IgA

RSV (respiratory syncytial virus), Fgp [Homo sapiens] Mus musculus OraVax Inc. (Cambridge MA USA) Respiratory Syncytial Virus (RSV) disease Phase III [a] [n]
125 ImmuRAIT-LL2 IG Murine IgG2a

radiolabelled with Iodine-131, I-131		 Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Non-Hodgkin's lymphoma (NHL) Phase I/II [e] (31)
127 Lym-1 IG Murine IgG2a

HLA-DR10 [Homo sapiens] Mus musculus Peregrine Pharmaceuticals Inc. (Tustin CA USA) Cancers Preclinical [p]
128 MAK-195F IG Murine F(ab')2

TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2) [Homo sapiens] Mus musculus Abbott Laboratories (Abbott Park IL USA) / Knoll Pharmaceutical (Mount Olive NJ USA) Sepsis toxic shock Phase III [a] [b] [e]
129 MEDI-500,
T10B9		 IG Murine IgM

CD3 [Homo sapiens]
TRαβ (T cell receptor alpha/beta), complex [Homo sapiens] 		Mus musculus MedImmune Inc. (Gaithersburg MD USA) Graft-versus-host disease (GvHD) Phase III [a]
137 RING SCAN Murine

radiolabelled with Indium-111, In-111		 TAG 72 (tumour associated glycoprotein 72) [Homo sapiens] Mus musculus Neoprobe Corp. (Dublin OH USA) Rectal cancers [j] (31)
Breast cancers
Colon cancers
7 muMAb VEGF A.4.6.1,
muMAb VEGF A4.6.1,
muMAb-VEGF		 IG Murine IgG1

VEGFA (Vascular Endothelial Growth Factor A) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Cancers E.coli (Escherichia coli) [c] [6]
114 AVICIDIN® IG Murine

radiolabelled with Yttrium-90, Y-90		 EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM) [Homo sapiens] Mus musculus NeoRx Corp. (Seattle WA USA) Prostate cancers Phase II [e] (31) (35)
Ovarian cancers Phase II
Colon cancers Phase II
Non-Hodgkin's lymphoma (NHL) Phase I

up

Chimeric

Number of results: 28

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT/mAb-DB receptor type IMGT/mAb-DB species Isotype and format Conjugated/ Radiolabelled Specificity target name
[species]		 Origin clone species Origin clone name Company Clinical indication Development status Regulatory agency status and year Expression Application Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
146 abciximab 7200 70
(1993)		 34
(1994)		 c7E3 REOPRO® IG Chimeric IgG1κ Fab

CD41/CD61, INTEGRIN-ALPHA-IIb_BETA-3, αIIbβ3, GPIIbIIIa, Fibrinogen receptor [Homo sapiens] Mus musculus 7E3 Centocor Inc. (Horsham PA USA) / Eli Lilly (Indianapolis IN USA) Refractory unstable angina when percutaneous coronary intervention is planned Phase M FDA approval November 1997 Sp2/0 mouse myeloma cells Therapeutic Cardiology FDA: (BLA) 103575

Drugnum: 332

 [a] [b] [e] [f] [j]
Anti-platelet prevention of blood clots in the setting of high risk percutaneous transluminal coronary angioplasty Phase M FDA approval December 1994 Sp2/0 mouse myeloma cells Therapeutic Cardiology
148 basiliximab 7578 76
(1996)		 38
(1997)		 CHI621 SIMULECT® IG Chimeric IgG1κ

IL2RA (interleukin-2 receptor, alpha subunit; IL-2RA; TAC; CD25) [Homo sapiens] Mus musculus CHI621 Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Renal transplant rejection
(Prevention)
Phase M FDA approval May 1998 Sp2/0 mouse myeloma cells Therapeutic Immunology FDA: (BLA) 103764

Drugnum: 440

 [a] [b] [d] [f] [j] [56]
149 bavituximab 8734 95
(2006)		 57
(2007)		 Tarvacin ch3G4 IG Chimeric IgG1κ

Phosphatidylserine [Homo sapiens] Mus musculus Peregrine Pharmaceuticals Inc. (Tustin CA USA) Hepatitis C Phase I Therapeutic Infectiology [p]
Breast cancers Phase II
Influenza Preclinical Therapeutic Infectiology
Non-small cell lung cancers (NSCLC) Phase II
151 cetuximab 7906 82
(1999)		 44
(2000)		 Fab C225,
IMC-225		 ERBITUX® IG Chimeric IgG1κ

EGFR (Epidermal Growth Factor Receptor; ERBB1; HER1; ERBB) [Homo sapiens] Mus musculus C225 ImClone Systems Inc. (Somerville NJ USA) (US) / Merck & Co., Inc. (Whitehouse Station NJ USA) (EU) Colorectal cancers, metastatic Phase M FDA approval February 2004 Sp2/0 mouse myeloma cells Therapeutic Oncology FDA: (BLA) 125084

NCI: C1723

Drugnum: 850

 [a] [b] [e] [j]
152 clenoliximab 7615 77
(1997)		 39
(1998)		 CE9γ4PE,
IDEC-151		 PRIMATIZED® IG Chimeric IgG4λ

CD4 (p55) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) / GlaxoSmithKline (Brentford UK) Rheumatoid arthritis (RA) Phase II Therapeutic Immunology [a] [b] (21)
Asthma Phase II Therapeutic Immunology
274 ecromeximab 8239 87
(2002)		 49
(2003)		 FPIA Chimeric

Unknown Unknown
154 galiximab 8339 89
(2003)		 51
(2004)		 IDEC-114 IG Chimeric IgG1λ

CD80, B7 [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) Rheumatoid arthritis (RA) Therapeutic Immunology NCI: C26447

 [a] [g]
Non-Hodgkin's lymphoma (NHL) Phase II Therapeutic Oncology
Psoriasis Phase II Therapeutic Immunology
328 girentuximab 9116 101
(2009)		 cG250,
WX-G250		 RENCAREX® IG Chimeric IgG1κ

Carbonic anhydrase IX (CAIX, CA9, MN, G250) [Homo sapiens] Wilex AG (Munich Germany) Renal cell carcinoma (RCC)
(Treatment)
Phase III Therapeutic Oncology
156 infliximab 7602 77
(1997)		 39
(1998)		 cA2 REMICADE® IG Chimeric IgG1

TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2) [Homo sapiens] Mus musculus A2 Centocor Inc. (Horsham PA USA) Ulcerative colitis Phase M FDA approval October 2006 Sp2/0 mouse myeloma cells Therapeutic Immunology FDA: (BLA) 103772

NCI: C1789

Drugnum: 703

Drugnum: 759

 [a] [b] [d] [f] [j] [53] [54]
Crohn's disease (CD)
(Treatment)
Phase M FDA approval August 1998 Sp2/0 mouse myeloma cells Therapeutic Immunology
Ankylosing spondylitis (AS) Phase M FDA approval December 2004 Sp2/0 mouse myeloma cells Therapeutic Immunology
Rheumatoid arthritis (RA) Phase M FDA approval November 1999 Sp2/0 mouse myeloma cells Therapeutic Immunology
Psoriatic arthritis (PSA) Phase M FDA approval May 2005 Sp2/0 mouse myeloma cells Therapeutic Immunology
329 iodine (124I) girentuximab 9117 101
(2009)		 124I_cG250,
124I_WX-G250		 REDECTANE® IG Chimeric IgG1κ

radiolabelled with Iodine-124, I-124		 Carbonic anhydrase IX (CAIX, CA9, MN, G250) [Homo sapiens] Wilex AG (Munich Germany) Kidney tumours
(Treatment)
Phase III Diagnostic Oncology (31)
Renal mass
157 keliximab 7560 76
(1996)		 38
(1997)		 IDEC CE9.1/SB-210396 IG Chimeric IgG1λ

CD4 (p55) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) Rheumatoid arthritis (RA)
(Treatment)
(chronic)		 Therapeutic Immunology (21)
158 lumiliximab 8443 90
(2004)		 52
(2004)		 IDEC-152,
P5E8		 IG Chimeric IgG1κ

FCER2 (Immunoglobulin E receptor type II; CD23) [Homo sapiens] Macaca fascicularis Biogen IDEC Pharmaceuticals (Cambridge MA USA) Allergic asthma Phase I Therapeutic Immunology NCI: C26448

 [a] [h] [i]
Chronic lymphocytic leukemia (CLL) Phase I Therapeutic Oncology
253 pagibaximab 8643 93
(2005)		 55
(2006)		 IG Chimeric IgG1κ

lipoteichoic acid [Staphylococcus epidermidis] Mus musculus Unknown Unknown
160 priliximab 7263 72
(1994)		 35
(1995)		 cm-MT412 IG Chimeric IgG1κ

CD4 (p55) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) Crohn's disease (CD) Phase II Therapeutic Immunology
161 rituximab 7609 77
(1997)		 39
(1998)		 IDEC-C2B8 MABTHERA®
RITUXAN® (US, Canada and Japan) 		IG Chimeric IgG1κ

MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35) [Homo sapiens] Mus musculus IDEC-C2B8 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Genzyme Corp. (Cambridge MA USA) Rheumatoid arthritis (RA) Phase M FDA approval March 2006 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Therapeutic Immunology FDA: (BLA) 103705


FDA: (BLA) 103737

NCI: C1702

Drugnum: 349

 [a] [b] [d] [f] [j] (18) [55]
Non-Hodgkin's lymphoma (NHL)
(Treatment)
(Follicular CD20 positive, relapsed or refractory low grade)		 Phase M FDA approval November 1997 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Therapeutic Oncology
297 siltuximab 9051 100
(2008)		 62
(2009)		 CLLB8,
CNTO 328		 IG Chimeric IgG1κ

IL6 (interleukin 6; IL-6) [Homo sapiens] Centocor Inc. (Horsham PA USA) Neoplasms Phase I Therapeutic Oncology
Multiple myeloma Phase II Therapeutic Hematology, Oncology
Renal cell carcinoma (RCC) Phase II Therapeutic Oncology
276 teneliximab 8211 87
(2002)		 49
(2003)		 IG Chimeric

Unknown Unknown
277 vapaliximab 8207 87
(2002)		 49
(2003)		 IG Chimeric

Unknown Unknown
256 volociximab 8600 93
(2005)		 55
(2006)		 IG Chimeric IgG4

INTEGRIN-ALPHA-5_BETA-1, α5β1, VLA5, Fibronectin receptor [Homo sapiens] Mus musculus p200-M Unknown Unknown NCI: C48426
143 131I-chTNT (Tumor Necrosis Therapy) -1/B COTARA® Chimeric

radiolabelled with Iodine-131, I-131		 Mus musculus Peregrine Pharmaceuticals Inc. (Tustin CA USA) Solid tumors Phase II [b] (31)
Glioblastoma multiforme (GBM) Phase III
Malignant glioma (brain cancers) Phase II
144 14,18 Chimeric

Mus musculus National Cancer Institute (Bethesda MD USA) Neuroblastoma Phase II NCI trial [b] [e]
Melanoma Phase II NCI trial
Leukemia Phase II NCI trial
Solid tumors Phase II NCI trial
145 90Y-cT84.66 Chimeric

CEACAM5 (carcinoembryonic antigen; CEA; CD66e) [Homo sapiens] Mus musculus T84.66 Beckman Research Institute (Duarte CA USA) Cancers Phase I [p] [59]
147 ALG-991 Chimeric

Mus musculus Allergene (San Mateo CA USA) Poison ivy Phase III [e]
Poison oak Phase III
150 BMS-182248,
BR96		 Chimeric conjugated with Bougainvillea spectabilis Willd bouganin

 Lewis Y [Homo sapiens] Mus musculus Bristol-Myers Squibb (Princeton NJ USA) Ovarian cancers Phase II E.coli (Escherichia coli) [c] [e] [14]
Breast cancers Phase II E.coli (Escherichia coli)
155 IC14 Chimeric

CD14 [Homo sapiens] Mus musculus 28C5 ICOS Corporation (Bothell WA USA) Sepsis toxic shock (severe) Phase I CHO (Chinese Hamster Ovary) cells [a] [b]
179 IMC-1C11 Chimeric

VEGFA (Vascular Endothelial Growth Factor A) [Homo sapiens] ImClone Systems Inc. (Somerville NJ USA) Angiogenesis
(Prevention)
NCI: C2037
159 Lym-1 radiolabelled,
Oncolym		 ONCOLYM® IG Chimeric IgG2a

radiolabelled with Iodine-131, I-131		 HLA-DR10 [Homo sapiens] Mus musculus Alpha Therapeutic Corp. (Los Angeles CA USA) / Peregrine Pharmaceuticals Inc. (Tustin CA USA) Non-Hodgkin's lymphoma (NHL) Phase III [e] [p] (19) (31)
153 CORSEVIN™ M IG Chimeric Fab

Factor VII [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / Corvas International Inc. (San Diego CA USA) Anticoagulant Phase I [a] [e]

up

Humanized

Number of results: 140

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT/mAb-DB receptor type IMGT/mAb-DB species Isotype and format Conjugated/ Radiolabelled Specificity target name
[species]		 Origin clone species Origin clone name Company Clinical indication Development status Regulatory agency status and year Expression Application Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
238 afutuzumab 9043 99
(2008)		 GA101 IG Humanized IgG1κ

MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35) [Homo sapiens] Mus musculus B-ly1 Biogen IDEC Pharmaceuticals (Cambridge MA USA) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) Non-Hodgkin's lymphoma (NHL) Therapeutic Oncology [p]
233 alacizumab pegol 8976 98
(2007)		 60
(2008)		 CDP791,
g165 DFM-PEG		 IG Humanized Fab'

KDR (kinase insert domain receptor; VEGFR2, Vascular endothelial growth factor receptor 2; VEGF-R2; FLK1; CD309) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Cancers Therapeutic Oncology
11 alemtuzumab 8005 83
(2000)		 45
(2001)		 Campath-1H,
LDP-03		 CAMPATH® (US)
MABCAMPATH® (EU) 		IG Humanized IgG1κ

CD52 [Homo sapiens] Rattus norvegicus YTH34.5HL Berlex Inc. (Wayne NJ USA) (US) / Genzyme Corp. (Cambridge MA USA) (EU) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) (EU/US) Chronic lymphocytic leukemia (CLL) Phase M FDA approval May 2001 CHO (Chinese Hamster Ovary) cells Therapeutic Hematology, Oncology FDA: (BLA) 103948

NCI: C1681

Drugnum: 702

 [a] [b] [c] [19]
Kidney transplant rejection Phase I/II CHO (Chinese Hamster Ovary) cells Diagnostic Immunology
Multiple sclerosis (MS) Phase I/II CHO (Chinese Hamster Ovary) cells Therapeutic Immunology
231 anrukinzumab 8942 98
(2007)		 60
(2008)		 IMA-638 IG Humanized IgG1

IL13 (interleukin 13; IL-13) [Homo sapiens] Mus musculus IMA-638 Wyeth Pharmaceuticals (Madison NJ USA) Asthma Phase II
18 apolizumab 8210 87
(2002)		 49
(2003)		 REMITOGEN™
SMART™ 1D10 		IG Humanized IgG1

HLA-DRB (HLA-DR beta) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) Chronic lymphocytic leukemia (CLL) (refractory) Phase II Therapeutic Hematology, Oncology NCI: C2228

 [b]
Non-Hodgkin's lymphoma (NHL) Phase II Therapeutic Oncology
272 aselizumab 8291 88
(2003)		 50
(2003)		 IG Humanized

Unknown Unknown
252 bapineuzumab 8624 93
(2005)		 55
(2006)		 AAB-001 IG Humanized IgG1

Amyloid beta (A beta) [Homo sapiens] Mus musculus Johnson & Johnson (Langhorne PA USA) / Pfizer (New York NY USA) Alzheimer's disease Phase III Therapeutic Neurology (32) (33)
334 benralizumab 9233 102
(2009)		 BIW-8405,
MEDI-563		 IG Humanized IgG1κ afucosylated

IL5RA (interleukin 5 receptor subunit alpha; CD125) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Asthma Phase II Therapeutic Immunology
24 bevacizumab 8017 83
(2000)		 45
(2001)		 12-IgG1,
F(ab)-12 IgG1,
Fab-12 IgG1,
rhuMAb-VEGF		 AVASTIN® IG Humanized IgG1

VEGFA (Vascular Endothelial Growth Factor A) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) / NIH (Bethesda MD USA) Renal cancers Phase II NCI trial FDA: (BLA) 125085

Drugnum: 851

 [a] [b] (20)
Genentech Inc. (S. San Francisco CA USA) (EU) Colorectal cancers, metastatic, carcinoma Phase M FDA approval February 2004 CHO (Chinese Hamster Ovary) cells Therapeutic Oncology
Breast cancers (metastatic HER2 negative) Phase M FDA approval February 2008 CHO (Chinese Hamster Ovary) cells Therapeutic Oncology
Non-small cell lung cancers, metastatic Phase M FDA approval October 2006 CHO (Chinese Hamster Ovary) cells Therapeutic Oncology
Colorectal cancers, metastatic Phase M FDA approval June 2006 CHO (Chinese Hamster Ovary) cells Therapeutic Oncology
283 bivatuzumab 7965 83
(2000)		 45
(2001)		 IG Humanized

Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) Squamous cancers Phase I Market discontinued (skin toxicity) February 2005 Therapeutic Oncology
52 cantuzumab mertansine 8223 89
(2003)		 51
(2004)		 huC242-DMI,
SB408075		 IG Humanized

Mus musculus GlaxoSmithKline (Brentford UK) / ImmunoGen Inc. (Cambridge MA USA) Pancreatic cancers Phase I/II Therapeutic Oncology [b]
Colorectal cancers Phase I/II Therapeutic Oncology
Non-small cell lung cancers (NSCLC) Phase I/II Therapeutic Oncology
78 cedelizumab 7567 77
(1997)		 39
(1998)		 ORTHOCLONE OKT4 A IG Humanized IgG

CD4 (p55) [Homo sapiens] Mus musculus Ortho Biotech Products LP (Bridgewater NJ USA) Allograft rejection
(Prevention)
Phase II Therapeutic Immunology [a] [b]
Autoimmune diseases, CD4 mediated
(Treatment)
Phase II Therapeutic Immunology
242 certolizumab pegol 8448 90
(2004)		 52
(2004)		 CDP870,
PHA-738144		 CIMZIA® IG Humanized PEGylated Fab'

TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Crohn's disease (CD) Phase M FDA approval April 2008 Therapeutic Immunology FDA: (BLA) 125160
Rheumatoid arthritis (RA) Phase III Therapeutic Immunology
236 citatuzumab bogatox 9046 99
(2008)		 61
(2009)		 VB6-845 IG Humanized IgG1κ Fab conjugated with Bougainvillea spectabilis Willd bouganin

 EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM) [Homo sapiens] Mus musculus Viventia Biotechnologies Inc. (Mississauga ON Canada) Solid tumors Phase I Therapeutic Oncology (29)
232 dacetuzumab 8959 98
(2007)		 60
(2008)		 huS2C,
SGN-40		 IG Humanized IgG1

CD40 (tumor necrosis factor receptor superfamily member 5; TNFRSF5) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) / Seattle genetics, Inc. (Bothell WA USA) Non-Hodgkin's lymphoma (NHL) Phase I Therapeutic Oncology [p]
Multiple myeloma Phase I Therapeutic Hematology, Oncology
Diffuse large B-cell lymphoma (DLBCL) Phase II Therapeutic Oncology
36 daclizumab 7164 78
(1997)		 40
(1998)		 ZENAPAX® IG Humanized IgG1

IL2RA (interleukin-2 receptor, alpha subunit; IL-2RA; TAC; CD25) [Homo sapiens] Mus musculus 1H4 F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) Acute kidney transplant rejection
(Prevention)
Phase M FDA approval December 1997 Sp2/0 mouse myeloma cells Therapeutic Immunology FDA: (BLA) 103749

NCI: C1569

Drugnum: 359

 [b] [c] [j] [46] [50]
PDL (Protein Design Labs) BioPharma (Fremont CA USA) Blood cancers Phase II
Pediatric kidney transplantation Phase I/II
Ulcerative colitis Phase II
Graft-versus-host disease (GvHD) Phase II
Psoriasis Phase II
Asthma Phase II
Uveitis Phase I/II
Liver transplantation Phase II
Tropical spastic paraparesis (model for multiple sclerosis) Phase I/II
333 dalotuzumab 9200 102
(2009)		 MK-0646 IG Humanized IgG1κ

IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221) [Homo sapiens] Merck & Co., Inc. (Whitehouse Station NJ USA) Solid tumors Phase I Therapeutic Oncology NCI: C70411
37 eculizumab 8231 87
(2002)		 49
(2003)		 5G1.1 SOLIRIS™ IG Humanized IgG

C5 (complement 5) [Homo sapiens] Mus musculus Alexion Pharmaceuticals Inc. (New Haven CT USA) Paroxysmal nocturnal hemoglobinuria (PNH) Phase M FDA approval March 2007 Therapeutic Hematology FDA: (BLA) 125166

NCI: C48386

Drugnum: 945

 [a] [b]
Dermatomyositis Phase I/II
Psoriasis Phase I/II
Nephritis Phase II
Rheumatoid arthritis (RA) Phase II
38 efalizumab 8122 85
(2001)		 47
(2002)		 hu1124 RAPTIVA® IG Humanized IgG1κ

ITGAL (INTEGRIN-ALPHA-L; LFA-1, lymphocyte function associated antigen 1; CD11a) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) (EU/US) / Merck Serono International S.A. (Geneva Switzerland) (EU) / Xoma (Berkeley CA USA) (US) Psoriasis (infection in chronic moderate to severe plaque) Withdrawn FDA withdrawal (risk of developing progressive multifocal leukoencephalopathy) March 2009, FDA approval October 2003 CHO (Chinese Hamster Ovary) cells Therapeutic Immunology FDA: (BLA) 125075

NCI: C68831

 [a] [b] [j]
291 elotuzumab 9074 100
(2008)		 62
(2009)		 HuLuc63,
PDL-063,
PDL063		 IG Humanized IgG1κ

SLAM7 (SLAM family member 7; CD2 subset 1; CS1; CRACC, CD2-like receptor-activating cytotoxic cells; 19A24; CD319) [Homo sapiens] Homo sapiens PDL (Protein Design Labs) BioPharma (Fremont CA USA) Multiple myeloma Phase I Therapeutic Hematology, Oncology
40 epratuzumab 7920 82
(1999)		 44
(2000)		 LYMPHOCIDE™ IG Humanized IgG1

CD22 (BL-CAM) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Non-Hodgkin's lymphoma (NHL) Phase I/II Therapeutic Oncology [a] [b] [e] (31)
Systemic lupus erythematosus (SLE) Therapeutic Immunology
280 erlizumab 8076 84
(2000)		 46
(2001)		 IG Humanized

Unknown Unknown
240 etaracizumab 8862 99
(2008)		 61
(2009)		 hLM60,
MEDI-522		 VITAXIN® IG Humanized IgG1

ITGAV/ITGB3 (INTEGRIN-ALPHA-V_BETA-3; αvβ3; CD51/CD61; CD51/GPIIIa; CD51/platelet membrane glycoprotein IIIa; VNR, vitronectin receptor; AlphaVbeta3 integrin) [Homo sapiens] Mus musculus LM609 MedImmune Inc. (Gaithersburg MD USA) Sarcoma Phase II Therapeutic Oncology [a]
Melanoma, metastatic Phase II Therapeutic Oncology
292 farletuzumab 9067 100
(2008)		 62
(2009)		 M3,
MORAb-003		 IG Humanized IgG1κ

FOLR1 (folate receptor 1; FR-alpha, folate receptor alpha; FBP, adult folate-binding protein) ovarian tumor-associated antigen MOv18 [Homo sapiens] Homo sapiens Morphotek Inc. (Exton PA USA) Ovarian cancers Phase II EC Orphan drug April 2008 Therapeutic Oncology
86 felvizumab 7623 77
(1997)		 39
(1998)		 SB 209763 IG Humanized IgG1

RSV (respiratory syncytial virus) [virus] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) Respiratory Syncytial Virus (RSV) disease
(Treatment)
(Prophylaxis)		 Phase III Therapeutic Infectiology, Pulmonary, Respiratory diseases [e]
43 fontolizumab 8264 87
(2002)		 49
(2003)		 IG Humanized IgG1

IFNG (interferon gamma; IFN gamma) [Homo sapiens] Mus musculus Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Crohn's disease (CD) Phase I/II Therapeutic Immunology
44 gemtuzumab 8024 83
(2000)		 45
(2001)		 CMA-676,
gemtuzumab ozogamicin		 MYLOTARG® IG Humanized IgG4κ conjugated with calicheamicin

 CD33 (SIGLEC3; SIGLEC-3; gp67; p67) [Homo sapiens] Mus musculus P67.6 Pfizer (New York NY USA) Acute myeloid leukemia (AML) (CD33 positive) Withdrawn FDA withdrawal (by Pfizer, on concerns about the product's safety and absence of clinical benefit in trials) June 2010, FDA approval May 2000 Therapeutic Hematology, Oncology [f] [j] (17) (33)
332 glembatumumab 9199 102
(2009)		 64
(2010)		 CDX-011,
CR011-vcMMAE,
glembatumumab vedotin		 IG Humanized IgG2κ conjugated with monomethyl auristatin E (MMAE)

 GPNB (glycoprotein transmembrane NMB, hematopoeitic growth factor inducible neurokinin-1 type, HGFIN), extracellular domain [Homo sapiens] Celldex Therapeutics, Inc. (Needham USA) Breast cancers Phase II Therapeutic Oncology (29)
Melanoma, metastatic Phase II Therapeutic Oncology
241 ibalizumab 8818 97
(2007)		 59
(2008)		 Hu5A8,
TNX-355		 IG Humanized IgG4

CD4 (p55) [Homo sapiens] Mus musculus Tanox Inc. (Houston TX USA) HIV infection, AIDS Phase II Therapeutic Infectiology [l]
259 inotuzumab ozogamicin 8574 92
(2004)		 54
(2005)		 CMC-544 IG Humanized IgG4κ conjugated with calicheamicin

 CD22 [Homo sapiens] Mus musculus G544 Wyeth Pharmaceuticals (Madison NJ USA) Non-Hodgkin's lymphoma (NHL) Phase II Therapeutic Oncology
Diffuse large B cell lymphoma Phase II Therapeutic Oncology
62 labetuzumab 8127 85
(2001)		 47
(2002)		 hMN14 CEACIDE™ IG Humanized IgG

CEACAM5 (carcinoembryonic antigen; CEA; CD66e) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Colorectal cancers Phase I/II Therapeutic Oncology NCI: C2043

 [b]
325 lebrikizumab 9165 101
(2009)		 MILR1444A,
PRO301444		 IG Humanized IgG4κ

IL13 (interleukin 13; IL-13) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Allergic asthma Therapeutic Immunology
53 lintuzumab 7580 76
(1996)		 38
(1997)		 HuM195,
Huma195-gelonin,
SGN-33,
SGN-70		 ZAMYL™
SMART™ M195 		IG Humanized IgG

CD33 (SIGLEC3; SIGLEC-3; gp67; p67) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / Seattle genetics, Inc. (Bothell WA USA) Autoimmune diseases Phase I Sp2/0 mouse myeloma cells (ATCC CRL 1581) Therapeutic Immunology [b] [32]
Acute myeloid leukemia (AML) Phase III Sp2/0 mouse myeloma cells (ATCC CRL 1581) Therapeutic Hematology, Oncology
Myelodysplastic syndrome Phase II Sp2/0 mouse myeloma cells (ATCC CRL 1581) Therapeutic Hematology, Oncology
39 matuzumab 8103 88
(2003)		 50
(2003)		 EMD-72000,
EMD72000		 IG Humanized IgG1

EGFR (Epidermal Growth Factor Receptor; ERBB1; HER1; ERBB), (epitope on external domain) [Homo sapiens] Mus musculus 425 Merck Serono International S.A. (Geneva Switzerland) / Takeda Pharmaceutical Co. Ltd. (Osaka Japan) Gastric cancers
(Treatment)
Phase II Therapeutic Oncology [c] [k] [4]
Lung cancers
(Treatment)
Phase II Therapeutic Oncology
335 mavrilimumab 9234 102
(2009)		 CAM-3001 IG Humanized IgG1λ

CSF2RA (granulocyte-macrophage colony-stimulating factor receptor subunit alpha, GM-CSF-R-alpha, CD116) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Rheumatoid arthritis (RA) Phase I Therapeutic Immunology
87 mepolizumab 7876 81
(1999)		 43
(2000)		 SB-240563 Bosatria® IG Humanized

IL5 (interleukin 5; IL-5) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Atopic dermatitis Phase II Therapeutic Immunology [a]
Asthma Phase II Therapeutic Immunology
Hypereosinophilic syndrome (HES) Phase III Therapeutic Hematology
135 milatuzumab 8922 98
(2007)		 60
(2008)		 hLL1,
MEDI-115		 IG Humanized IgG1

CD74 (major histocompatibility complex class II invariant chain) [Homo sapiens] Mus musculus MedImmune Inc. (Gaithersburg MD USA) Multiple myeloma Therapeutic Hematology, Oncology
73 motavizumab 8693 95
(2006)		 57
(2007)		 MEDI-524 NUMAX® IG Humanized IgG1κ

RSV (respiratory syncytial virus)
F glycoprotein (fusion protein) 		Mus musculus MedImmune Inc. (Gaithersburg MD USA) Respiratory Syncytial Virus (RSV) disease
(Prevention)
Phase III Therapeutic Infectiology [p]
75 natalizumab 7716 79
(1998)		 41
(1999)		 AN100226 TYSABRI®
ANTEGREN® (formerly) 		IG Humanized IgG4

INTEGRIN-ALPHA-4_BETA-1, α4β1, VLA4, VCAM1 receptor [Homo sapiens] Mus musculus AN100226m Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Elan Pharmaceuticals International Ltd. (Dublin Ireland) Colitis Phase II Therapeutic Hereditary inflammatory diseases FDA: (BLA) 125104

Drugnum: 869

 [a] [b] [c] [e] [j] [k] (3) (4) [7]
Inflammatory conditions, acute and chronic COS cells transient expression Therapeutic Immunology
Multiple sclerosis (MS) Phase M FDA SBLA reintroduced June 2006, Market suspension (three patients developed progressive multifocal leukoencephalopathy (PML)) February 2005, FDA approval November 2004 NSO mouse myeloma cells Therapeutic Immunology
Crohn's disease (CD) Phase M FDA approval January 2008 NSO mouse myeloma cells Therapeutic Immunology
76 nimotuzumab 8545 94
(2005)		 56
(2006)		 hR3,
Theraloc		 THERACIM® (India, China, Cuba, Argentina, Columbia) IG Humanized IgG1κ

EGFR (Epidermal Growth Factor Receptor; ERBB1; HER1; ERBB) [Homo sapiens] Mus musculus YM BioScienecs Inc. (Mississauga Canada) Pancreatic cancers Phase M EMA Orphan drug June 2008 NSO mouse myeloma cells Therapeutic Oncology NCI: C2733

 [n]
Pancreatic cancers, metastatic Phase II
Head cancers Phase M NSO mouse myeloma cells Therapeutic Oncology
Glioma cancers Phase M EMA withdrawal December 2008, EMA Orphan drug September 2004 NSO mouse myeloma cells Therapeutic Oncology
Neck cancers Phase M NSO mouse myeloma cells Therapeutic Oncology
Lung cancers Phase II
227 ocrelizumab 8636 94
(2005)		 56
(2006)		 2H7 IG Humanized IgG1

MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA) Rheumatoid arthritis (RA) Phase III Therapeutic Immunology NCI: C66250
Systemic lupus erythematosus (SLE) Phase III Therapeutic Immunology
Multiple sclerosis (MS) (relapsing remitting) Phase II Therapeutic Immunology
Lupus nephritis Phase III Therapeutic Immunology
77 omalizumab 8039 84
(2000)		 46
(2001)		 IGE25,
olizumab,
rhuMab-E25		 XOLAIR® IG Humanized IgG1κ

IgE, CH3 [Homo sapiens] Mus musculus MaE11 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA) Allergic asthma Phase M CHO (Chinese Hamster Ovary) cells Therapeutic Immunology FDA: (BLA) 103976

NCI: C29299

 [a] [b] [l]
Asthma, severe persistent Phase M FDA approval (for subcutaneous use) June 2003 CHO (Chinese Hamster Ovary) cells Therapeutic Immunology
237 oportuzumab monatox 9045 100
(2008)		 62
(2009)		 VB4-845 PROXINIUM™
VICINIUM™ 		IG Humanized scFv conjugated with Pseudomonas aeruginosa exotoxin A

 EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM) [Homo sapiens] Homo sapiens Viventia Biotechnologies Inc. (Mississauga ON Canada) Bladder cancers Phase II FDA Orphan drug (US) February 2005 Therapeutic Oncology (29)
Head cancers Phase II/III FDA Orphan drug (US) February 2005 Therapeutic Oncology
Neck cancers Phase II/III FDA Orphan drug (US) February 2005 Therapeutic Oncology
79 palivizumab 7753 79
(1998)		 41
(1999)		 MEDI-493 SYNAGIS® IG Humanized IgG1κ

RSV (respiratory syncytial virus)
F glycoprotein (fusion protein) 		Mus musculus Abbott Laboratories (Abbott Park IL USA) (EU) / MedImmune Inc. (Gaithersburg MD USA) (US) Respiratory Syncytial Virus (RSV) disease (prophylaxis of lower respiratory tract disease in pediatric patients) Phase M AMM Market authorization (Abbott) August 1999, FDA approval June 1998 NSO mouse myeloma cells Therapeutic Pulmonary, Respiratory diseases FDA: (BLA) 103770

NCI: C2625

Drugnum: 447

 [a] [b] [d] [j] [49]
88 pascolizumab 8227 87
(2002)		 49
(2003)		 SB-240683 IG Humanized

IL4 (interleukin 4; IL-4) [Homo sapiens] Mus musculus Centocor Inc. (Horsham PA USA) / GlaxoSmithKline (Brentford UK) Asthma Phase II Therapeutic Immunology [a]
Allergy Phase II Therapeutic Immunology
80 pertuzumab 8380 89
(2003)		 51
(2004)		 rhuMAB 2C4 OMNITARG™ IG Humanized IgG1κ

ERBB2 (Epidermal Growth Factor Receptor 2; HER-2; p185c-erbB2; NEU; EGFR2) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Breast cancers Phase III Therapeutic Oncology NCI: C38692
Prostate cancers Phase II Therapeutic Oncology
81 pexelizumab 8153 85
(2001)		 47
(2002)		 5G1.1-SC IG Humanized scFv

C5 (complement 5) [Homo sapiens] Mus musculus Alexion Pharmaceuticals Inc. (New Haven CT USA) Cardiopulmonary bypass Phase III Therapeutic Cardiology [a]
Myocardial infarction Phase II Therapeutic Cardiology
84 ranibizumab 8313 90
(2004)		 52
(2004)		 Fab-12 variant Y0317,
RhuFab		 LUCENTIS® IG Humanized Fab

VEGFA (Vascular Endothelial Growth Factor A) [Homo sapiens] Mus musculus muMAb-VEGF, muMAb VEGF A.4.6.1, muMAb VEGF A4.6.1 Genentech Inc. (S. San Francisco CA USA) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Age related macular degeneration (AMD), neovascular (wet) Phase M FDA approval June 2006 E.coli (Escherichia coli) Therapeutic Ophthalmology FDA: (BLA) 125156

Drugnum: 904
279 reslizumab 8106 85
(2001)		 47
(2002)		 IG Humanized

Unknown Unknown
327 rontalizumab 9114 101
(2009)		 RhuMAB IFNalpha IG Humanized IgG1κ

IFNA (IFN alpha; interferon alpha) [Homo sapiens] Genentech Inc. (S. San Francisco CA USA) Systemic lupus erythematosus (SLE)
(Treatment)
Phase II Therapeutic Immunology
304 rovelizumab 7869 81
(1999)		 43
(2000)		 IG Humanized

Unknown Unknown
17 ruplizumab 8014 83
(2000)		 45
(2001)		 BG-9588,
hu5c8		 Antova™ IG Humanized IgG1κ

CD40LG (CD40 ligand; CD40L; TNFSF5, tumor necrosis factor ligand superfamily member 5; TRAP, tumor necrosis factor related activation protein) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) Allograft rejection Phase I/II Therapeutic Immunology [a]
Systemic lupus erythematosus (SLE) Phase II Therapeutic Immunology
285 sibrotuzumab 7866 81
(1999)		 43
(2000)		 IG Humanized

Unknown Unknown
71 siplizumab 8251 87
(2002)		 49
(2003)		 MEDI-507 IG Humanized

CD2 (LFA-2, Lymphocyte function antigen 2) [Homo sapiens] Rattus sp. BT1-322 BioTransplant (Charlestown MA USA) / MedImmune Inc. (Gaithersburg MD USA) Graft-versus-host disease (GvHD) Phase II Therapeutic Immunology [a] [b]
Acute kidney transplant rejection Phase I/II Therapeutic Immunology
MedImmune Inc. (Gaithersburg MD USA) Psoriasis Phase II Therapeutic Immunology
298 solanezumab 9097 100
(2008)		 62
(2009)		 LY2062430 IG Humanized IgG1κ

Amyloid-beta (Abeta) peptide soluble monomer [Homo sapiens] Homo sapiens Eli Lilly (Indianapolis IN USA) Alzheimer's disease Phase II Therapeutic Neurology
251 sontuzumab 8438 94
(2005)		 56
(2006)		 AS1402,
huHMFG-1		 IG Humanized IgG1

MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin, episialin) [Homo sapiens]
Episialin [Homo sapiens] 		Mus musculus Antisoma (London UK) Breast cancers Phase I Therapeutic Oncology
330 suvizumab 9185 102
(2009)		 KD-247 IG Humanized IgG1

HIV-1 (human immunodeficiency virus), IIIB gp120 V3 loop [virus] The Chemo-Sero-Therapeutic Research Institute (Kumamoto Japan ) HIV infection, AIDS
(Treatment)
Phase I Unknown Infectiology [63]
103 tadocizumab 8651 94
(2005)		 56
(2006)		 C4G1,
YM-337		 IG Humanized IgG1

CD41/CD61, INTEGRIN-ALPHA-IIb_BETA-3, αIIbβ3, GPIIbIIIa, Fibrinogen receptor, platelet [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / Yamanouchi USA (White Plains NY USA) Platelet aggregation Phase II Therapeutic Hematology [b]
271 talizumab 8370 89
(2003)		 51
(2004)		 IG Humanized

Unknown Unknown
230 tanezumab 8941 99
(2008)		 61
(2009)		 RN624 IG Humanized IgG2

NGF (nerve growth factor; NGFB, beta polypeptide) [Homo sapiens] Mus musculus Pfizer (New York NY USA) Pain, severe acute Phase II Therapeutic Neurology
Pain chronic Phase II Therapeutic Neurology
261 tefibazumab 8500 92
(2004)		 54
(2005)		 IG Humanized

Unknown Unknown
92 teplizumab 8869 97
(2007)		 59
(2008)		 hOKT3-gamma-1 (Ala-Ala),
humanized OKT3,
MGA031		 IG Humanized IgG1κ

CD3E (CD3 epsilon) [Homo sapiens] Mus musculus OKT3 MacroGenics Inc. (Rockville MD USA) Type 1 diabetes Phase I/II CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells, COS-1 cells transient expression and larger scale preparation in roller bottles Therapeutic Immunology [c] [37]
234 tigatuzumab 8979 98
(2007)		 60
(2008)		 CS-1008,
TRA-8		 IG Humanized IgG1

TNFRSF10B (tumor necrosis factor receptor superfamily member 10B; DR5, death receptor 5; TRAIL-R2, TNF-related apoptosis-inducing ligand receptor 2; TR-2; CD262) [Homo sapiens] Mus musculus Daiichi Sankyo Inc. (Parsippany NJ USA) Unknown
96 tocilizumab 8394 90
(2004)		 52
(2004)		 atlizumab,
MRA,
rhPM-1		 ACTEMRA™
RoACTEMRA® (EU) 		IG Humanized IgG1κ

IL6R (interleukin 6 receptor; IL-6R) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) Multiple myeloma CHO (Chinese Hamster Ovary) DHFR cells EMEA: H-C-955

ATC: L04AC07

 [c] (5) [38]
Lymphoproliferative disorder giant lymph node hyperplasia (Castleman's disease) Phase III NDA approval April 2005 CHO (Chinese Hamster Ovary) DHFR cells
Rheumatoid arthritis (RA) Phase III EMA approval November 2008 CHO (Chinese Hamster Ovary) DHFR cells Therapeutic Immunology
60 toralizumab 8232 87
(2002)		 49
(2003)		 E6040,
IDEC-131		 IG Humanized

CD40LG (CD40 ligand; CD40L; TNFSF5, tumor necrosis factor ligand superfamily member 5; TRAP, tumor necrosis factor related activation protein) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) / Eisai Co. Ltd. (Tokyo Japan) Multiple sclerosis (MS) Phase II Therapeutic Immunology [a] [b]
Systemic lupus erythematosus (SLE) Phase I Therapeutic Immunology
97 trastuzumab 7637 78
(1997)		 40
(1998)		 4D5V8,
Herceptin		 HERCEPTIN® IG Humanized IgG1κ

ERBB2 (Epidermal Growth Factor Receptor 2; HER-2; p185c-erbB2; NEU; EGFR2) [Homo sapiens] Mus musculus 4D5 F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Genentech Inc. (S. San Francisco CA USA) (US) Breast cancers overexpressing ERBB2, metastatic Phase M AMM Market authorization (Roche) August 2000, FDA approval October 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Therapeutic Oncology FDA: (BLA) 103792

NCI: C1647

Drugnum: 485

 [a] [b] [d] [e] [j] [48]
Breast cancers (as adjuvant) Phase III CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells
Non-small cell lung cancers (NSCLC) Phase II CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells
254 tucotuzumab celmoleukin 8652 94
(2005)		 56
(2006)		 EMD 273066,
huKS-IL2,
KSA-Interleukin-2		 FPIA Humanized IgG1

EPCAM (epithelial cell adhesion molecule; TACSTD1, Tumor-associated calcium signal transducer 1; GA733-2, gastrointestinal tumor-associated protein 2; EGP-2, epithelial glycoprotein 2; Ep-CAM, epithelial cell adhesion molecule; KSA; KS1/4 antigen; M4S; tumor antigen 17-1A; CD326; EpCAM) Merck Serono International S.A. (Geneva Switzerland) Ovarian cancers Phase II Therapeutic Oncology
Small cell lung cancers (SCLC) Phase II Therapeutic Oncology
265 urtoxazumab 8276 90
(2004)		 52
(2004)		 IG Humanized

Unknown Unknown
300 vedolizumab 9093 100
(2008)		 62
(2009)		 LDP-02,
LDP02,
MLN-02,
MLN0002,
MLN02		 IG Humanized IgG1κ

INTEGRIN-ALPHA-4_BETA-7, α4β7, LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1) [Homo sapiens] Homo sapiens Genentech Inc. (S. San Francisco CA USA) / Millennium Pharmaceuticals Inc. (Cambridge MA USA) / MRC Technology (UK) Inflammatory bowel disease (IBD) Phase II Therapeutic Immunology [a] [b] [k]
Ulcerative colitis Phase II Therapeutic Immunology
21 veltuzumab 8932 98
(2007)		 60
(2008)		 hA20,
IMMU-106		 IG Humanized IgG1

MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35) [Homo sapiens] Mus musculus MedImmune Inc. (Gaithersburg MD USA) Non-Hodgkin's lymphoma (NHL) Phase I Therapeutic Oncology
100 visilizumab 8054 84
(2000)		 46
(2001)		 HuM291 NUVION®
SMART™ anti-CD3 		IG Humanized IgG2

CD3E (CD3 epsilon) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) Intravenous steroid-refractory ulcerative colitis (IVSR-UC) Phase I/II Therapeutic Immunology NCI: C2687

 [a] [b]
Allograft rejection Phase I/II Therapeutic Immunology
Kidney transplantation Phase II Therapeutic Immunology
Autoimmune diseases Phase I Therapeutic Immunology
Psoriasis Phase I/II Therapeutic Immunology
229 yttrium (90 Y) clivatuzumab tetraxetan 9226 102
(2009)		 64
(2010)		 IG Humanized IgG1κ conjugated wih chelator tetraxetan

radiolabelled with Yttrium-90, Y-90		 MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin, episialin) [Homo sapiens] Immunomedics Inc. (Morris Plains NJ USA) Pancreatic cancers, metastatic Phase I/II Diagnostic Oncology (31)
255 yttrium (90Y) tacatuzumab tetraxetan 8484 91
(2004)		 55
(2006)		 hAFP-31 AFP-Cide™ IG Humanized IgG1 conjugated wih chelator tetraxetan

radiolabelled with Yttrium-90, Y-90		 Alpha fetoprotein (α-fetoprotein) [Homo sapiens] Mus musculus Immunomedics Inc. (Morris Plains NJ USA) Cancers Therapeutic Oncology (31)
1 0.5B,
0.5beta		 IG Humanized IgG1

HIV-1 (human immunodeficiency virus), IIIB gp120 V3 loop [virus] Mus musculus Kaketsuken (Kumamoto Japan) / MRC Technology (UK) HIV infection, AIDS
(Prevention and treatment)
Preclinical COS cells transient expression [c] [k] (1) [1]
2 15 Humanized

4F2, CD98hc (CD98 heavy chain), FRP-1 (fusion regulatory protein 1) [Homo sapiens] Mus musculus Merck KgaA (Darmstadt Germany) / MRC Technology (UK) Cancers Unknown Oncology
3 1B4 IG Humanized IgG4

ITGB2 (INTEGRIN-BETA-2; CD18) [Homo sapiens] Mus musculus Merck & Co., Inc. (Whitehouse Station NJ USA) / NIH (Bethesda MD USA) Acute inflammatory disease CV1P cells [c] [2]
4 3α4D10 IG Humanized IgG1

Toxin, (epitope ARGFAK) [Clostridium perfringens] Mus musculus Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Gas gangrene YB2/0 rat myeloma cells [c] [3]
220 520C9XH22,
MDX-210		 IG Humanized Fab (520C9)
IgG1 (H22)

CD3E (CD3 epsilon) [Homo sapiens]
FCGR1 (FCGR1A, FCGR1B, FCGR1C) (Fc gamma RI; CD64) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		Partially Humanized Ciba-Geigy AG (Basel Switzerland) / Medarex (Princeton NJ USA) All HER2-positive malignancies Phase I/II [e] (36)
5 5c8 Humanized

CD40LG (CD40 ligand; CD40L; TNFSF5, tumor necrosis factor ligand superfamily member 5; TRAP, tumor necrosis factor related activation protein) [Homo sapiens] Mus musculus Biogen IDEC Pharmaceuticals (Cambridge MA USA) / MRC Technology (UK) Inflammation Unknown Immunology [k]
Autoimmune diseases Unknown Immunology
6 60,3 IG Humanized IgG1

ITGB2 (INTEGRIN-BETA-2; CD18) [Homo sapiens] Mus musculus Bristol-Myers Squibb (Princeton NJ USA) Myocardial infarction Ag8.653 mouse myeloma cells [c] (2) [5]
33 7F11C7,
CTM01		 IG Humanized IgG4

MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin, episialin) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Ovarian cancers NSO mouse myeloma cells, Transient in CHO (Chinese Hamster Ovary) L761h cells [c] (6) (7) [18]
Breast cancers
34 ABC-48,
CY-174		 Humanized

SELP (P-selectin; CD62P) [Homo sapiens] Mus musculus Cytel Corporation (San Diego CA USA) / MRC Technology (UK) Inflammation Preclinical [k]
35 ABC-88,
CY-178		 Humanized

SELE (E-selectin; CD62E) [Homo sapiens] Mus musculus Cytel Corporation (San Diego CA USA) / MRC Technology (UK) Inflammation [k]
9 AD-159 Humanized

HIV (human immunodeficiency virus), gp120 [virus] Mus musculus Tanox Inc. (Houston TX USA) HIV infection, AIDS Phase I/II [a]
10 AD-439 Humanized

HIV (human immunodeficiency virus), gp120 V3 loop [virus] Mus musculus Tanox Inc. (Houston TX USA) HIV infection, AIDS Phase II [a] [e]
257 AS1409,
BC1-IL12,
huBC1-huIL12		 FPIA Humanized

ED-B (extra domain B) of fibronectin [Homo sapiens] Antisoma (London UK) Renal cancers Phase I
Melanoma Phase I
19 AT13/5 IG Humanized IgG1

CD38 [Homo sapiens] Mus musculus Tenovus Research (UK) / Wellcome (London UK) Multiple myeloma CHO (Chinese Hamster Ovary) cells, NSO mouse myeloma cells Therapeutic Hematology, Oncology [c] [8]
20 AUK12-20 IG Humanized IgG1

IL6R (interleukin 6 receptor; IL-6R) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Japan) / MRC Technology (UK) / Osaka University Medical School (Osaka Japan) IL6 dependent tumors COS cells transient expression [c] [k] (5) [9]
16 Anti-TAC 90 Υ-HAT IG Humanized

Mus musculus National Cancer Institute (Bethesda MD USA) Lymphoma Phase II NCI trial
22 BAT STIMUMAB™ IG Humanized IgG1

T cell transmembrane protein [Homo sapiens] Mus musculus CureTech (Yavne Israel) / MRC Technology (UK) Cancers Preclinical [k]
30 BAY 103356,
BAY W 3356,
CDP571		 Humicade™ IG Humanized IgG4

TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Crohn's disease (CD) Phase II [a]
Rheumatoid arthritis (RA) Phase II
23 BC-1 Humanized

ED-B (extra domain B) of fibronectin [Homo sapiens] Mus musculus Antisoma (London UK) / MRC Technology (UK) Angiogenesis Preclinical [k] [51]
25 BMA 031 IG Humanized IgG1

TRαβ (T cell receptor alpha/beta) [Homo sapiens] Mus musculus Behringwerke Aktiengesellschaft (Marburg Germany) / Genzyme Corp. (Cambridge MA USA) Graft-versus-host disease (GvHD) Sp2/0 mouse myeloma cells [c] [13]
Autoimmunity Sp2/0 mouse myeloma cells
Transplantation Sp2/0 mouse myeloma cells
27 BW431/26 IG Humanized IgG3

CEACAM5 (carcinoembryonic antigen; CEA; CD66e) [Homo sapiens] Mus musculus Behringwerke Aktiengesellschaft (Marburg Germany) / MRC Laboratory of Molecular Biology (Cambridge UK) Colorectal cancers
(Treatment)
BHK cells (ATCC CCL 10) [c] [15]
Breast cancers
(Treatment)
BHK cells (ATCC CCL 10)
Lung cancers
(Treatment)
BHK cells (ATCC CCL 10)
26 BrE-3 IG Humanized IgG1

MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin, episialin) [Homo sapiens] Mus musculus Cancer Research Fund of Contra Costa (Walnut Creek CA USA) / NIH (Bethesda MD USA) Breast cancers Sp2/0-Ag14 mouse myeloma cells [c] [16]
95 C21/AL-90,
HU-901,
TNX-901		 Humanized

IgE [Homo sapiens] Mus musculus MRC Technology (UK) / Novartis (Basel Switzerland) / Tanox Inc. (Houston TX USA) Peanut allergy (severe) Phase II [b] [k] [l]
28 CAMPATH-9 Humanized

CD4 (p55) [Homo sapiens] Rattus sp. Pathology Dept., University of Cambridge (Cambridge UK) Establishment of immunological tolerance state CHO (Chinese Hamster Ovary) Dihydrofolate reductase-deficient cells [c] [20]
239 CAR RN 894777-94-7 Humanized scFv-Fc

MS4A1 (membrane-spanning 4-domains subfamily A member 1; CD20; B1, B lymphocyte surface antigen; Leu-16; Bp35) [Homo sapiens] Mus musculus Unknown Unknown
29 CC49 IG Humanized IgG1

TAG 72 (tumour associated glycoprotein 72) [Homo sapiens] Mus musculus NIH (Bethesda MD USA) Cancers Sp2/0 mouse myeloma cells Diagnostic, Therapeutic Oncology [c] [e] [17]
31 CDP850 Humanized

SELE (E-selectin; CD62E) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) Psoriasis Phase I [a]
32 CE25/B7 Humanized

CEACAM5 (carcinoembryonic antigen; CEA; CD66e) [Homo sapiens] Mus musculus MRC Technology (UK) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) Cancers [k]
41 Fd138-80 IG Humanized IgG1

HSV (herpes simple virus), gD glycoprotein [virus] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / University of Alabama (Tuscaloosa AL USA) Neutralisation activity of HSV-1 Sp2/0 mouse myeloma cells [c] [24]
42 Fd79 IG Humanized IgG1

HSV (herpes simple virus), gB glycoprotein [virus] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) / University of Alabama (Tuscaloosa AL USA) Neutralisation activity of HSV-1 Sp2/0 mouse myeloma cells [c] [24]
45 H17E2 IG Humanized IgG1

PLAP-like testicular alkaline phosphatase [Homo sapiens]
PLAP (placental alkaline phosphatase; EC 3.1.3.1) [Homo sapiens] 		Mus musculus Unilever (UK) Ovarian cancers
(Treatment)
NSO mouse myeloma cells [c] [25]
Testicular cancers
(Treatment)
NSO mouse myeloma cells
46 H52 IG Humanized IgG1

ITGB2 (INTEGRIN-BETA-2; CD18) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Potential to ameliorate deleterious immunological and inflammatory processes E.coli (Escherichia coli) [c] [26]
47 HCMV16 IG Humanized IgG1

HCMV (human cytomegalovirus), gH envelope glycoprotein [virus] Mus musculus Royal Free Hospital School of Medicine (London UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Human cytomegalovirus (HCMV)
(Prevention and treatment)
(infections in immunocompromised patients (Passive immunisation either alone or in combination with antiviral agents))		 NSO mouse myeloma cells, YB2/0 rat myeloma cells [c] [27]
48 HCMV37 IG Humanized IgG1

HCMV (human cytomegalovirus), gB envelope glycoprotein [virus] Mus musculus Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Human cytomegalovirus (HCMV) (Herpes infections in immunocompromised individuals) YB2/0 rat myeloma cells [c] [28]
49 HMFG1 IG Humanized IgG1

MUC1 (mucin1; CD227; PEM, polymorphic epithelial mucin, episialin), (epitope PDTR) [Homo sapiens] Mus musculus The Netherlands CRC Labs (Nottingham UK) / Unilever (UK) Neoplasms of epithelial origin, particularly carcinomas of breast, ovary, cervix, bronchus, and gastrointestinal tract NSO mouse myeloma cells [c] (7) [29]
51 Hu23F2G LEUKARREST™ Humanized

Mus musculus ICOS Corporation (Bothell WA USA) Ischemic stroke Phase III [b]
59 ICM3 Humanized

ICAM3 (intercellular adhesion molecule 3; CD50; ICAM-3) [Homo sapiens] Mus musculus ICOS Corporation (Bothell WA USA) Psoriasis Phase I/II [a]
61 JES1-39D10 IG Humanized IgG4

IL5 (interleukin 5; IL-5) [Homo sapiens] Rattus sp. Schering-Plough (Kenilworth NJ USA) / University of Alabama (Tuscaloosa AL USA) IL5 induced eosinophils diseases (eg asthma) COS cells transient expression [c] [30]
106 KB001 HUMANEERED™ IG Humanized Fab'

PcrV (located at the tip of the syringe-like TTSS (Type Three Secretion System)) [virus] Mus musculus KaloBios Pharmaceuticals Inc. (Palo Alto CA USA) Pseudomonas aeruginosa infections Phase I/II [p]
63 LDP-01,
MLNM2201		 IG Humanized IgG

ITGB2 (INTEGRIN-BETA-2; CD18) [Homo sapiens] Mus musculus Millennium Pharmaceuticals Inc. (Cambridge MA USA) Allograft rejection (in kidney transplantation) [a] [b]
Stroke Phase I/II
66 M22 IG Humanized IgG1

FCGR1 (FCGR1A, FCGR1B, FCGR1C) (Fc gamma RI; CD64) [Homo sapiens] Mus musculus Dartmouth Medical School (Hanover NH USA) / Medarex (Princeton NJ USA) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) Immunotherapy directed against human high affinity receptor for the Fc portion of IgG NSO mouse myeloma cells [c] [33]
67 M4 IG Humanized IgG1

TAG 72 (tumour associated glycoprotein 72), (epitope sialosyl-Tn) [Homo sapiens] Mus musculus University of Saskatchewan (Saskatchewan Canada) Gastric cancers Sp2/0-Ag14 mouse myeloma cells [c] [12]
Ovarian cancers Sp2/0-Ag14 mouse myeloma cells
Colorectal cancers Sp2/0-Ag14 mouse myeloma cells
221 MDX-220 Humanized

TAG 72 (tumour associated glycoprotein 72) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		Partially Humanized Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Acute myeloid leukemia (AML) Phase I (36)
222 MDX-447 Humanized

EGFR (Epidermal Growth Factor Receptor; ERBB1; HER1; ERBB) [Homo sapiens]
Bispecific (two different variable domain binding sites (Fv)) [Homo sapiens] 		Partially Humanized Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Cancers Phase II (36)
69 MDX-CD4 IG Humanized IgG

CD4 (p55) [Homo sapiens] Mus musculus Eisai Co. Ltd. (Tokyo Japan) / Genmab A/S (Copenhagen Denmark) / Medarex (Princeton NJ USA) Rheumatoid arthritis (RA) Phase I [a]
70 ME361 Humanized

GD2 ganglioside [Homo sapiens] Mus musculus Merck KgaA (Darmstadt Germany) / MRC Technology (UK) Cancers
347 MEDI-528 IG Humanized IgG1

IL9 (interleukin 9; IL-9) [Homo sapiens] MedImmune Inc. (Gaithersburg MD USA) Asthma Phase II
68 MaE11 IG Humanized IgG1

IgE [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) IgE mediated allergies Adenovirus transformed human embryonic 293 kidney cells [c] [34]
72 MikB1 IG Humanized IgG1

IL2RB (interleukin-2 receptor, beta; IL-2R; p70; CD122) [Homo sapiens] Mus musculus F. Hoffmann-La Roche Ltd. (Basel Switzerland) (EU) / Kyoto-Katsura Hospital (Kyoto Japan) / National Cancer Institute (Bethesda MD USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Graft-versus-host disease (GvHD) Sp2/0 mouse myeloma cells [c] [35]
Allograft rejection
(Prevention)
(in conjunction with humanized anti-Tac)		 Sp2/0 mouse myeloma cells
Autoimmune diseases Sp2/0 mouse myeloma cells
82 PRO542 Humanized

HIV (human immunodeficiency virus), gp120 [virus] Mus musculus Genzyme Corp. (Cambridge MA USA) / Progenics Pharmaceuticals Inc. (Tarrytown NY USA) HIV infection, AIDS Phase I/II [a]
85 RSV19 IG Humanized IgG1

RSV (respiratory syncytial virus), fusion protein (F glycoprotein) [virus] Mus musculus AFRC Inst. Animal Health (UK) / Scotgen Biopharmaceuticals Ltd. (Aberdeen UK) / University of Aberdeen (Aberdeen UK) Respiratory Syncytial Virus (RSV) disease (acute respiratory illness in young children) YB2/0 rat myeloma cells (from ATCC) [c] [39]
89 SCH55700 Humanized

IL5 (interleukin 5; IL-5) [Homo sapiens] Mus musculus Celltech, UCB (Brussels Belgium) / Schering AG (Berlin Germany) Asthma Phase I [a]
Allergy Phase I
91 SK2 IG Humanized IgG1

IL6 (interleukin 6; IL-6) [Homo sapiens] Mus musculus Chugai pharmaceuticals Co. Ltd. (Japan) / F. Hoffmann-La Roche Ltd. (Basel Switzerland) Cardiac myxoma CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression [c] [40]
HIV infection, AIDS CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression
Rheumatoid arthritis (RA) CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression
Increased levels of IL6 in sepsis CHO (Chinese Hamster Ovary) cells, COS-7 cells transient expression
93 TES-C21 IG Humanized IgG1

IgE, free and bound to B cells [Homo sapiens] Mus musculus Ciba-Geigy AG (Basel Switzerland) / MRC Laboratory of Molecular Biology (Cambridge UK) Immediate-type hypersensitivities COS cells transient expression, NSO mouse myeloma cells [c] [41]
104 YFC51.1 IG Humanized IgG1
IgG4

ITGB2 (INTEGRIN-BETA-2; CD18) [Homo sapiens] Rattus sp. Cambridge University (Cambridge UK) / Wellcome (London UK) Influx of leukocytes in Sepsis or reperfusion injury, adult respiratory distress syndrome and graft rejection
(Prevention)
COS cells transient expression, NSO mouse myeloma cells [c] (2) [43]
105 YTH12.5 IG Humanized IgG1

CD3E (CD3 epsilon) [Homo sapiens] Rattus sp. Cambridge University (Cambridge UK) T cell lymphoma CHO (Chinese Hamster Ovary) DHFR cells [c] [44]
Autoimmunity CHO (Chinese Hamster Ovary) DHFR cells
Organ rejection CHO (Chinese Hamster Ovary) DHFR cells
13 anti-B4 IG Humanized IgG1

CD19 (B lymphocyte surface antigen B4; Leu-12) [Homo sapiens] Mus musculus ImmunoGen Inc. (Cambridge MA USA) / University Bath (Bath UK) B cell malignancies COS cells transient expression [c] [45]
14 anti-CD18 IG Humanized F(ab')2

ITGB2 (INTEGRIN-BETA-2; CD18) [Homo sapiens] Mus musculus Genentech Inc. (S. San Francisco CA USA) Acute myocardial infarction Phase II [a] [b]
15 anti-IL4 Humanized

IL4 (interleukin 4; IL-4) [Homo sapiens] Mus musculus PDL (Protein Design Labs) BioPharma (Fremont CA USA) Asthma Phase I [b]
50 hT84.66,
T84.66 M5A		 Humanized

CEACAM5 (carcinoembryonic antigen; CEA; CD66e) [Homo sapiens] Mus musculus T84.66 Beckman Research Institute (Duarte CA USA) Colorectal cancers, metastatic [p] [58]
54 humanized B1-8 IG Humanized IgE

Hapten NP-cap (4-hydroxy-3-nitrophenacethyl caproic acid) [Homo sapiens]
NIP-cap (3-iodo-4-hydroxy-5-nitrophenyl-acetyl caproic acid) [Homo sapiens] 		Mus musculus B1-8 MRC Laboratory of Molecular Biology (Cambridge UK) Unknown Proof of concept Stably transformed J558L cells [c] [10]
55 humanized D1.3 IG Humanized IgG1
IgG2

Lysozyme [Homo sapiens] Mus musculus D1.3 MRC Laboratory of Molecular Biology (Cambridge UK) Unknown Proof of concept J558L mouse myeloma cells, NSO mouse myeloma cells [c] [21] [22]
56 humanized DX48 IG Humanized IgG1

Digoxin [Homo sapiens] Rattus sp. DX48 Wellcome (London UK) Unknown Proof of concept [c] [23]
57 humanized K20 IG Humanized IgG1

ITGB1 (INTEGRIN-BETA-1; CD29) [Homo sapiens] Mus musculus MuK20 INSERM (Montpellier France) / LIGM (Montpellier France) Immunosuppression Proof of concept Insect cells, NSO mouse myeloma cells Unknown Immunology [c] [31]
74 mu-39.1 Humanized

HIV-1 (human immunodeficiency virus) [virus] Mus musculus Kaketsuken (Kumamoto Japan) / MRC Technology (UK) HIV infection, AIDS [k]
83 PROTOVIR™ IG Humanized IgG1

HCMV (human cytomegalovirus) [virus] Mus musculus Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / PDL (Protein Design Labs) BioPharma (Fremont CA USA) Human cytomegalovirus (HCMV) Phase III [a]
12 ALLOMUNE™ Humanized

CD2 (LFA-2, Lymphocyte function antigen 2) [Homo sapiens] Mus musculus BioTransplant (Charlestown MA USA) Hodgkin's disease (HD) Phase I [b]
Non-Hodgkin's lymphoma (NHL) (refractory) Phase I

up

Chimeric (Light Chain)

Number of results: 1

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT/mAb-DB receptor type IMGT/mAb-DB species Isotype and format Conjugated/ Radiolabelled Specificity target name
[species]		 Origin clone species Origin clone name Company Clinical indication Development status Regulatory agency status and year Expression Application Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
235 otelixizumab 8864 98
(2007)		 60
(2008)		 ChAglyCD,
TRX4		 IG Chimeric (Light Chain)
Humanized (Heavy Chain) 		IgG1λ

CD3E (CD3 epsilon) [Homo sapiens] Rattus sp. YTH12.5 GlaxoSmithKline (Brentford UK) Psoriasis Phase I Therapeutic Immunology
TolerRx (Cambridge CA USA) Type 1 diabetes Phase III Therapeutic Immunology

up

Humanized (Heavy Chain)

Number of results: 1

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT/mAb-DB receptor type IMGT/mAb-DB species Isotype and format Conjugated/ Radiolabelled Specificity target name
[species]		 Origin clone species Origin clone name Company Clinical indication Development status Regulatory agency status and year Expression Application Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
235 otelixizumab 8864 98
(2007)		 60
(2008)		 ChAglyCD,
TRX4		 IG Chimeric (Light Chain)
Humanized (Heavy Chain) 		IgG1λ

CD3E (CD3 epsilon) [Homo sapiens] Rattus sp. YTH12.5 GlaxoSmithKline (Brentford UK) Psoriasis Phase I Therapeutic Immunology
TolerRx (Cambridge CA USA) Type 1 diabetes Phase III Therapeutic Immunology

up

Immunoadhesin

Number of results: 9

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT/mAb-DB receptor type IMGT/mAb-DB species Fusion protein format Conjugated/ Radiolabelled Specificity target name
[species]		 Origin clone species Origin clone name Company Clinical indication Development status Regulatory agency status and year Expression Application Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
212 abatacept 8495 91
(2004)		 53
(2005)		 BMS-188667,
CTLA4-Ig		 ORENCIA® FPIA Immunoadhesin CTLA4-IGHG1 Fc

CD80, B7 [Homo sapiens]
CD86 [Homo sapiens] 		Homo sapiens Bristol-Myers Squibb (Princeton NJ USA) Rheumatoid arthritis (RA) Phase M FDA approval December 2005 CHO (Chinese Hamster Ovary) cells Therapeutic Immunology FDA: (BLA) 125118

Drugnum: 888

 [j] [n] (16) (30)
Graft-versus-host disease (GvHD) (solid organ transplant) Phase I CHO (Chinese Hamster Ovary) cells Therapeutic Immunology
T cell co-stimulation modulator Phase M FDA approval December 2005 CHO (Chinese Hamster Ovary) cells Therapeutic Immunology
Psoriasis Phase I CHO (Chinese Hamster Ovary) cells Therapeutic Immunology
214 aflibercept 8739 95
(2006)		 57
(2007)		 VEGF Trap,
VEGF Trap R1/R2,
VEGF-trapR1,
VEGF-TRAPR1R2		 FPIA Immunoadhesin Vascular endothelial growth factor receptor 1, (VEGFR1, FLT1, TRT) - VEGFR2 (KDR, FLK1, CD309)-IGHG1 Fc

VEGFA (Vascular Endothelial Growth Factor A) [Homo sapiens] Homo sapiens Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) / Sanofi-Aventis (Paris France) Ovarian cancers Phase II Therapeutic Oncology [p] (30)
215 alefacept 8059 84
(2000)		 46
(2001)		 AMEVIVE® FPIA Immunoadhesin Leucocyte function associated antigen 3 (LFA3)-IGHG1 Fc

CD2 (LFA-2, Lymphocyte function antigen 2) [Homo sapiens] Homo sapiens Biogen Canada Inc. (Mississauga ON Canada) Psoriasis, severe chronic plaque Phase M FDA approval January 2003 CHO (Chinese Hamster Ovary) cells Therapeutic Immunology FDA: (BLA) 125036

Drugnum: 820

 [j] [n] (30)
213 atacicept 8669 95
(2006)		 57
(2007)		 TACI-Fc,
TACI-Ig		 FPIA Immunoadhesin Tumor necrosis factor receptor superfamily member 13B, (TNFR13B, TACI (Transmembrane Activator and CAML Interactor), CD267)-IGHG1 Fc

TNFSF13B (Tumor necrosis factor superfamily 13B; BAFF, B cell activating factor; BLyS, B lymphocyte activator; CD257; TNFS13, tumor necrosis factor superfamily 13; APRIL, a proliferation-including ligand; CD256) Homo sapiens Merck Serono International S.A. (Geneva Switzerland) / ZymoGenetics Inc. (Seattle WA USA) Non-Hodgkin's lymphoma (NHL) Phase I Therapeutic Oncology [p] (30)
Multiple myeloma Phase I Therapeutic Hematology, Oncology
Systemic lupus erythematosus (SLE) Phase II Therapeutic Immunology
Rheumatoid arthritis (RA) Phase II Therapeutic Immunology
245 baminercept 8944 98
(2007)		 60
(2008)		 BG9924,
TT-47		 FPIA Immunoadhesin Tumor necrosis factor receptor superfamily member 3 (TNFRSF3, lymphotoxin beta receptor, LTBR, TNFCR)-IGHG1 Fc

LTBR (lymphotoxin beta receptor; TNFRSF3, tumor necrosis factor receptor superfamily member 3; TNFCR)-IGHG1 Fc [Homo sapiens] Homo sapiens Biogen IDEC Pharmaceuticals (Cambridge MA USA) Inflammatory bowel disease (IBD) Therapeutic Immunology (30)
Rheumatoid arthritis (RA) Therapeutic Immunology
247 belatacept 8627 93
(2005)		 59
(2008)		 BMS-224818,
LEA29Y		 FPIA Immunoadhesin CTLA4-IGHG1 Fc

CTLA4 [Homo sapiens] Bristol-Myers Squibb (Princeton NJ USA) Rheumatoid arthritis (RA) Therapeutic Immunology (30)
246 briobacept 8963 98
(2007)		 60
(2008)		 BR3-Fc,
SS-79		 FPIA Immunoadhesin TNFRSF13C (tumor necrosis factor receptor superfamily member 13C, BAFFR, BR3, B cell activating factor receptor, CD268)-IGHG1 Fc

TNFRSF13C (tumor necrosis factor receptor superfamily member 13C; BAFFR; BR3, B cell activating factor receptor; CD268)-IGHG1 Fc [Homo sapiens] Homo sapiens Genentech Inc. (S. San Francisco CA USA) Rheumatoid arthritis (RA) Phase I Therapeutic Immunology (30)
216 etanercept 7783 81
(1999)		 43
(2000)		 TNFR-immunoadhesin ENBREL® FPIA Immunoadhesin Tumor necrosis factor receptor (TNFR) alpha - IGHG1 Fc

TNF (tumor necrosis factor; TNFA, TNF-alpha; TNFSF2) [Homo sapiens] Homo sapiens Immunex Corporation Amgen (Thousand Oaks CA USA) Rheumatoid arthritis (RA) Phase M FDA approval November 1998 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Therapeutic Immunology FDA: (BLA) 103795

Drugnum: 737

 [f] [j] [n] (15) (30)
Psoriatic arthritis (PSA) Phase M FDA approval February 2002 CHO (Chinese Hamster Ovary) MTX (methotrexate resistant) cells Therapeutic Immunology
217 rilonacept 8750 95
(2006)		 57
(2007)		 ARCALYST™ FPIA Immunoadhesin Interleukin-1 receptor accessory protein (IL1RAP)-type 1 interleukin-1 receptor-IGHG1 Fc

IL1 (interleukin 1; IL-1) [Homo sapiens] Homo sapiens Regeneron Pharmaceuticals Inc. (Tarrytown NY USA) Autoinflammatory diseases Therapeutic Immunology FDA: (BLA) 125249

 [p] (30)
Rheumatoid arthritis (RA) Therapeutic Immunology
Osteoarthritis Therapeutic Immunology
Cryopyrin-Associated Periodic Syndromes (CAPS)
(Treatment)
(including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS))		 Phase M FDA approval February 2008 Therapeutic Hereditary inflammatory diseases, Immunology

up

Antibodies and immunoadhesins approved for therapeutic use and on the market (in 2010)

Number of results: 30

IMGT/mAb-DB ID INN (International Nonproprietary Name) INN Num. INN Prop. list INN Rec. list Common name Proprietary name IMGT/mAb-DB receptor type IMGT/mAb-DB species Fusion protein format Conjugated/ Radiolabelled Specificity target name
[species]		 Origin clone species Origin clone name Company Clinical indication Development status Regulatory agency status and year Expression Application Clinical domain FDA / EMA / NCI number or ATC code Citations/ Notes/ References
212 abatacept 8495 91
(2004)		 53
(2005)		 BMS-188667,
CTLA4-Ig		 ORENCIA® FPIA Immunoadhesin CTLA4-IGHG1 Fc

CD80, B7 [Homo sapiens]
CD86 [Homo sapiens] 		Homo sapiens Bristol-Myers Squibb (Princeton NJ USA) Rheumatoid arthritis (RA) Phase M FDA approval December 2005 CHO (Chinese Hamster Ovary) cells Therapeutic Immunology FDA: (BLA) 125118

Drugnum: 888

 [j] [n] (16) (30)
Graft-versus-host disease (GvHD) (solid organ transplant) Phase I CHO (Chinese Hamster Ovary) cells Therapeutic Immunology